<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alzm="http://alzamend.com/20241031"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alzm-20241031.xsd" xlink:type="simple"/>
    <context id="From2024-05-01to2024-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2024-12-10</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="From2024-08-012024-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-22_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_DirectorsAndOfficersLiabilityInsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:DirectorsAndOfficersLiabilityInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2016-04-30_custom_StockIncentivePlan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alzm:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="From2019-02-282019-03-01_custom_StockIncentivePlan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alzm:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-28</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="From2016-04-292016-04-30_srt_MaximumMember_custom_StockIncentivePlan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alzm:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-29</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alzm:PerformanceContingentStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alzm:KeyEmployeesAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-25</startDate>
            <endDate>2019-11-26</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UnamortizedStockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">alzm:UnamortizedStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">alzm:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-10-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-10-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_Warrant2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_Warrant2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-08-012024-08-19_custom_Warrant2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-19_custom_Warrant2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-19</instant>
        </period>
    </context>
    <context id="From2024-08-012024-08-21_custom_Warrant2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-21</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-21_custom_Warrant2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-21</instant>
        </period>
    </context>
    <context id="From2024-09-012024-09-11_custom_Warrant2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-11_custom_Warrant2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-11</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ExercisePrice1Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ExercisePrice1Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ExercisePrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ExercisePrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ExercisePrice5Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ExercisePrice5Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ExercisePrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2018-07-012018-07-02_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-02</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_FirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-02</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_SecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:SecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-02</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_ThirdAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:ThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-02</endDate>
        </period>
    </context>
    <context id="From2016-04-292016-05-02_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-29</startDate>
            <endDate>2016-05-02</endDate>
        </period>
    </context>
    <context id="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_FirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-29</startDate>
            <endDate>2016-05-02</endDate>
        </period>
    </context>
    <context id="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_SecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:SecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-29</startDate>
            <endDate>2016-05-02</endDate>
        </period>
    </context>
    <context id="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_ThirdAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:ThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-29</startDate>
            <endDate>2016-05-02</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-19</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_FirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-19</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_SecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:SecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-19</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_ThirdAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:ThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-19</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:PreIndMeetingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:PreIndMeetingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_IndApplicationFilingMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:IndApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_IndApplicationFilingMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:IndApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponFirstDosingOfPatientInClinicalTrialMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponFirstDosingOfPatientInClinicalTrialMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponCompletionOfFirstClinicalTrialMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponCompletionOfFirstClinicalTrialMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponFdaApprovalMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFdaApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponFdaApprovalMember_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFdaApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponINDApplicationFilingMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponINDApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponINDApplicationFilingMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponINDApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponCompletionOfFirstPhaseIIClinicalTrialMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponCompletionOfFirstPhaseIIClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponCompletionOfFirstPhaseIIClinicalTrialMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponCompletionOfFirstPhaseIIClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponFDABLAApprovalMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFDABLAApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponFDABLAApprovalMember_custom_ALZN002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFDABLAApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AdditionalAL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AdditionalAL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_FirstCommercialSaleMember_custom_AdditionalAL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:FirstCommercialSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-10-31_custom_FirstCommercialSaleMember_custom_AdditionalAL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:FirstCommercialSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-05-08_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-10</instant>
        </period>
    </context>
    <context id="From2024-05-012024-05-10_custom_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-10</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-25</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-25</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_custom_SeriesBConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementsMember_custom_AultLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alzm:AultLendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-26_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="From2024-03-012024-03-26_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-26_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="From2024-04-012024-04-29_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-04-29_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-29_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="From2024-11-012024-12-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-12-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-05-01to2024-10-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2024-05-01to2024-10-31" id="Fact000004">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-05-01to2024-10-31" id="Fact000005">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-05-01to2024-10-31" id="Fact000006">--04-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2024-05-01to2024-10-31" id="Fact000007">0001677077</dei:EntityCentralIndexKey>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-10-31"
      id="xdx2ixbrl0071"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0101"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0121"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:DividendsOnPreferredShares
      contextRef="From2023-08-012023-10-31"
      id="xdx2ixbrl0200"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:DividendsOnPreferredShares
      contextRef="From2023-05-012023-10-31"
      id="xdx2ixbrl0202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-07-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-07-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-012024-10-31"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-08-012024-10-31"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-07-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-07-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0334"
      unitRef="Shares"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-08-012023-10-31"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-08-012023-10-31"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-04-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-04-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-04-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0395"
      unitRef="Shares"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfNotePayableAndInterestToPreferredStock
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfNotePayableAndInterestToPreferredStock
      contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfNotePayableAndInterestToPreferredStock
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfNotePayableAndInterestToPreferredStock
      contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-04-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-04-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0480"
      unitRef="Shares"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-012023-10-31"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-05-012023-10-31"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0530"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-05-012023-10-31"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:IncreaseDecreaseInPrepaidExpensesRelatedParty
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-05-012023-10-31"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfSeriesConvertiblePreferredStock
      contextRef="From2023-05-012023-10-31"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock
      contextRef="From2023-05-012023-10-31"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock
      contextRef="From2023-05-012023-10-31"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:PrepaidClinicalTrialExpenses
      contextRef="AsOf2024-04-30"
      id="xdx2ixbrl0693"
      unitRef="USD"
      xsi:nil="true"/>
    <alzm:SharesAvailableForGrantOptionsGranted
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0729"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0731"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0733"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <alzm:SharesAvailableForGrantOptionsExercised
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0735"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0737"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0739"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0780"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0782"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0788"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-05-01to2024-10-31"
      id="xdx2ixbrl0790"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-08-012024-10-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      id="xdx2ixbrl0803"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-08-012023-10-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      id="xdx2ixbrl0805"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-05-012024-10-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-05-01to2024-10-31" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-05-01to2024-10-31" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-05-01to2024-10-31" id="Fact000015">2024-10-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-05-01to2024-10-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-05-01to2024-10-31" id="Fact000017">001-40483</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-05-01to2024-10-31" id="Fact000018">ALZAMEND NEURO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-05-01to2024-10-31" id="Fact000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-05-01to2024-10-31" id="Fact000020">81-1822909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-05-01to2024-10-31" id="Fact000021">3480 Peachtree Road NE</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-05-01to2024-10-31" id="Fact000022">Second Floor Suite 103</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-05-01to2024-10-31" id="Fact000023">Atlanta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-05-01to2024-10-31" id="Fact000024">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-05-01to2024-10-31" id="Fact000025">30326</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-05-01to2024-10-31" id="Fact000026">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-05-01to2024-10-31" id="Fact000027">722-6303</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-05-01to2024-10-31" id="Fact000028">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-05-01to2024-10-31" id="Fact000029">ALZN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-05-01to2024-10-31" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-05-01to2024-10-31" id="Fact000031">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-05-01to2024-10-31" id="Fact000032">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-05-01to2024-10-31" id="Fact000033">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-05-01to2024-10-31" id="Fact000034">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-05-01to2024-10-31" id="Fact000035">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-05-01to2024-10-31" id="Fact000036">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2024-05-01to2024-10-31" id="Fact000037">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-12-10"
      decimals="INF"
      id="Fact000039"
      unitRef="Shares">5432797</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000047"
      unitRef="USD">4093073</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">376048</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">673669</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000051"
      unitRef="USD">79194</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">4766742</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000054"
      unitRef="USD">455242</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">240976</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000057"
      unitRef="USD">176346</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">5007718</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000060"
      unitRef="USD">631588</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">1254750</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000069"
      unitRef="USD">2925059</us-gaap:AccountsPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000072"
      unitRef="USD">300714</us-gaap:NotesPayableCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">1254750</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000075"
      unitRef="USD">3225773</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000083"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000085"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <alzm:PreferredStockSharesDesignated
      contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000087"
      unitRef="Shares">3000</alzm:PreferredStockSharesDesignated>
    <alzm:PreferredStockSharesDesignated
      contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000089"
      unitRef="Shares">3000</alzm:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000091"
      unitRef="Shares">87.9867</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000093"
      unitRef="Shares">87.9867</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000095"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000097"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000103"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000105"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <alzm:PreferredStockSharesDesignated
      contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000107"
      unitRef="Shares">6000</alzm:PreferredStockSharesDesignated>
    <alzm:PreferredStockSharesDesignated
      contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000109"
      unitRef="Shares">6000</alzm:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000111"
      unitRef="Shares">2100</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000113"
      unitRef="Shares">2100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000115"
      unitRef="Shares">2100</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000117"
      unitRef="Shares">2100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000126"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000128"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000130"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000132"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000134"
      unitRef="Shares">5231254</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000136"
      unitRef="Shares">5231254</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000138"
      unitRef="Shares">687999</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000140"
      unitRef="Shares">687999</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">523</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000124"
      unitRef="USD">69</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">60162478</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000143"
      unitRef="USD">51426154</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">-56410033</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000146"
      unitRef="USD">-54020408</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">3752968</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000149"
      unitRef="USD">-2594185</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">5007718</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000152"
      unitRef="USD">631588</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">311088</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">1996783</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">517659</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">4362920</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000164"
      unitRef="USD">1046980</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">904939</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">1802814</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">2064732</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">1358068</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">2901722</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">2320473</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">6427652</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-1358068</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">-2901722</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">-2320473</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">-6427652</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">3495</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">4311</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">15501</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">6147</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-3495</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-4311</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">-15501</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-6147</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">-1361563</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">-2906033</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-2335974</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">-6433799</us-gaap:ProfitLoss>
    <alzm:DividendsOnPreferredShares
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">53651</alzm:DividendsOnPreferredShares>
    <alzm:DividendsOnPreferredShares
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">53651</alzm:DividendsOnPreferredShares>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-1415214</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">-2906033</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">-2389625</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">-6433799</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-08-012024-10-31"
      decimals="INF"
      id="Fact000209"
      unitRef="USDPShares">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-08-012024-10-31"
      decimals="INF"
      id="Fact000211"
      unitRef="USDPShares">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-08-012023-10-31"
      decimals="INF"
      id="Fact000213"
      unitRef="USDPShares">-4.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-08-012023-10-31"
      decimals="INF"
      id="Fact000215"
      unitRef="USDPShares">-4.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000217"
      unitRef="USDPShares">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000219"
      unitRef="USDPShares">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-05-012023-10-31"
      decimals="INF"
      id="Fact000221"
      unitRef="USDPShares">-9.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-05-012023-10-31"
      decimals="INF"
      id="Fact000223"
      unitRef="USDPShares">-9.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-08-012024-10-31"
      decimals="INF"
      id="Fact000225"
      unitRef="Shares">3531702</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-08-012024-10-31"
      decimals="INF"
      id="Fact000227"
      unitRef="Shares">3531702</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-08-012023-10-31"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">656378</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-08-012023-10-31"
      decimals="INF"
      id="Fact000231"
      unitRef="Shares">656378</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000233"
      unitRef="Shares">2154761</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000235"
      unitRef="Shares">2154761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-05-012023-10-31"
      decimals="INF"
      id="Fact000237"
      unitRef="Shares">656323</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-05-012023-10-31"
      decimals="INF"
      id="Fact000239"
      unitRef="Shares">656323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-07-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">188</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-07-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">2100</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000253"
      unitRef="Shares">861332</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-07-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">86</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000244"
      unitRef="USD">53782414</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-54994819</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-07-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">-1212319</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000263"
      unitRef="Shares">755888</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">76</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">1174148</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">1174224</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">83</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares
      contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">550</alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">5125000</alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000281"
      unitRef="USD">5125000</alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts>
    <alzm:ConversionOfPreferredStockToCommonStockShares
      contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000293"
      unitRef="Shares">-650</alzm:ConversionOfPreferredStockToCommonStockShares>
    <alzm:ConversionOfPreferredStockToCommonStockShares
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">3613951</alzm:ConversionOfPreferredStockToCommonStockShares>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">361</alzm:ConversionOfPreferredStockToCommonStock>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000288"
      unitRef="USD">-361</alzm:ConversionOfPreferredStockToCommonStock>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">81277</alzm:StockbasedCompensationToEmployeesAndConsultants>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">81277</alzm:StockbasedCompensationToEmployeesAndConsultants>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-1415214</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000311"
      unitRef="USD">-1415214</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000321"
      unitRef="Shares">88</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000323"
      unitRef="Shares">2100</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">5231254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">60162478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">-56410033</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">3752968</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000336"
      unitRef="Shares">646268</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-07-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">65</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">62370775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-14883295</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">-47600428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-07-31"
      decimals="0"
      id="Fact000332"
      unitRef="USD">-112883</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares
      contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000345"
      unitRef="Shares">615</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">18087</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">18087</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000354"
      unitRef="Shares">83</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-7002</alzm:SubscriptionReceivablePaymentReceived>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">7002</alzm:SubscriptionReceivablePaymentReceived>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">318336</alzm:StockbasedCompensationToEmployeesAndConsultants>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000368"
      unitRef="USD">318336</alzm:StockbasedCompensationToEmployeesAndConsultants>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-2906033</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-2906033</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000386"
      unitRef="Shares">646966</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">65</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000379"
      unitRef="USD">62700196</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      id="Fact000380"
      unitRef="USD">-14876293</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000381"
      unitRef="USD">-50506461</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31"
      decimals="0"
      id="Fact000382"
      unitRef="USD">-2682493</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-04-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">2100</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">687999</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-04-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">69</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-04-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">51426154</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-04-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">-54020408</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-2594185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">755888</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">76</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">1174148</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000406"
      unitRef="USD">1174224</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000417"
      unitRef="Shares">83</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000426"
      unitRef="Shares">800</alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">7088644</alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts>
    <alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000424"
      unitRef="USD">7088644</alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts>
    <alzm:ConversionOfPreferredStockToCommonStockShares
      contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000435"
      unitRef="Shares">-712</alzm:ConversionOfPreferredStockToCommonStockShares>
    <alzm:ConversionOfPreferredStockToCommonStockShares
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000437"
      unitRef="Shares">3787284</alzm:ConversionOfPreferredStockToCommonStockShares>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">378</alzm:ConversionOfPreferredStockToCommonStock>
    <alzm:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-378</alzm:ConversionOfPreferredStockToCommonStock>
    <alzm:ConversionOfNotePayableAndInterestToPreferredStock
      contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">311356</alzm:ConversionOfNotePayableAndInterestToPreferredStock>
    <alzm:ConversionOfNotePayableAndInterestToPreferredStock
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">311356</alzm:ConversionOfNotePayableAndInterestToPreferredStock>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000449"
      unitRef="USD">162554</alzm:StockbasedCompensationToEmployeesAndConsultants>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">162554</alzm:StockbasedCompensationToEmployeesAndConsultants>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000457"
      unitRef="USD">-2389625</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">-2389625</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000467"
      unitRef="Shares">88</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000469"
      unitRef="Shares">2100</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000471"
      unitRef="Shares">5231254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">60162478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000464"
      unitRef="USD">-56410033</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">3752968</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000482"
      unitRef="Shares">646268</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-04-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">65</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-04-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000475"
      unitRef="USD">62001395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-14883295</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-04-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000477"
      unitRef="USD">-44072662</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-04-30"
      decimals="0"
      id="Fact000478"
      unitRef="USD">3045503</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares
      contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000491"
      unitRef="Shares">615</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">18087</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">18087</alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000500"
      unitRef="Shares">83</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">-7002</alzm:SubscriptionReceivablePaymentReceived>
    <alzm:SubscriptionReceivablePaymentReceived
      contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      id="Fact000505"
      unitRef="USD">7002</alzm:SubscriptionReceivablePaymentReceived>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000511"
      unitRef="USD">687716</alzm:StockbasedCompensationToEmployeesAndConsultants>
    <alzm:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000514"
      unitRef="USD">687716</alzm:StockbasedCompensationToEmployeesAndConsultants>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">-6433799</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000521"
      unitRef="USD">-6433799</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000532"
      unitRef="Shares">646966</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000524"
      unitRef="USD">65</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000525"
      unitRef="USD">62700196</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      id="Fact000526"
      unitRef="USD">-14876293</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">-50506461</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-10-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">-2682493</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">-2389625</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">-6433799</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">25370</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000544"
      unitRef="USD">25370</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">9286</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">162554</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000550"
      unitRef="USD">687716</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000555"
      unitRef="USD">594475</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000556"
      unitRef="USD">134213</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <alzm:IncreaseDecreaseInPrepaidExpensesRelatedParty
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">-247334</alzm:IncreaseDecreaseInPrepaidExpensesRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">-1668953</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000562"
      unitRef="USD">795968</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000564"
      unitRef="USD">-4455843</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000565"
      unitRef="USD">-4811624</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">90000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000571"
      unitRef="USD">147243</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000573"
      unitRef="USD">-90000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000574"
      unitRef="USD">-147243</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000579"
      unitRef="USD">1174224</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000580"
      unitRef="USD">18087</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000582"
      unitRef="USD">7088644</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000585"
      unitRef="USD">8262868</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000586"
      unitRef="USD">18087</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">3717025</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000589"
      unitRef="USD">-4940780</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000591"
      unitRef="USD">376048</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-04-30"
      decimals="0"
      id="Fact000592"
      unitRef="USD">5140859</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">4093073</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-10-31"
      decimals="0"
      id="Fact000595"
      unitRef="USD">200079</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <alzm:ConversionOfSeriesConvertiblePreferredStock
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000603"
      unitRef="USD">7120133</alzm:ConversionOfSeriesConvertiblePreferredStock>
    <alzm:FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000606"
      unitRef="USD">1635489</alzm:FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock>
    <alzm:ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000609"
      unitRef="USD">311356</alzm:ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000612">&lt;p id="xdx_801_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z8f1nF8Q3Bx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_826_zPuVBmwzLSg2"&gt;DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Alzamend Neuro, Inc. (the
&#x201c;Company&#x201d; or &#x201c;Alzamend&#x201d;), is a clinical-stage biopharmaceutical company focused on developing novel products for
the treatment of Alzheimer&#x2019;s disease (&#x201c;Alzheimer&#x2019;s&#x201d;), bipolar disorder (&#x201c;BD&#x201d;), major depressive disorder
(&#x201c;MDD&#x201d;) and post-traumatic stress disorder (&#x201c;PTSD&#x201d;). With two current product candidates, Alzamend aims to bring
treatments or cures to market at a reasonable cost as quickly as possible. The Company&#x2019;s current pipeline consists of two novel
therapeutic drug candidates: (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate,
known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc.,
as licensor (the &#x201c;Licensor&#x201d;); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic
vaccine that seeks to restore the ability of a patient&#x2019;s immunological system to combat Alzheimer&#x2019;s, known as ALZN002, through
a royalty-bearing exclusive worldwide license from the same Licensor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company is devoting substantially
all its efforts towards research and development of its two product candidates and raising capital. The Company has not generated any
product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its
common stock, par value $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241031_zzC7M8bydA91" title="Common stock, par value (in dollars per share)"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241031_zp8gy3v77M9l" title="Preferred stock, par value (in dollars per share)"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share (&#x201c;Common Stock&#x201d;) and its preferred stock, par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240430_zq2wn0AUOCzb" title="Common stock, par value (in dollars per share)"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240430_zK0e3sAB2WXc" title="Preferred stock, par value (in dollars per share)"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. The Company
expects to continue to incur net losses in the foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On
October 27, 2023, pursuant to the authorization provided by the Company&#x2019;s stockholders at a special meeting of stockholders, the
Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company&#x2019;s issued and outstanding
Common Stock by a ratio of one-for-fifteen (the &#x201c;First Reverse Split&#x201d;). The First Reverse Split did not affect the number
of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the First Reverse Split,
each fifteen shares of Common Stock issued and outstanding prior to the First Reverse Split were converted into one share of Common Stock.
The First Reverse Split became effective in the State of Delaware on October 31, 2023. All share amounts in these financial statements
have been updated for all periods presented to reflect the First Reverse Split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On
July 10, 2024, pursuant to the authorization provided by the Company&#x2019;s stockholders at its annual meeting of stockholders, the Company
filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company&#x2019;s issued and outstanding
Common Stock by a ratio of one-for-ten (the &#x201c;Second Reverse Split&#x201d;). The Second Reverse Split did not affect the number of
authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the Second Reverse Split, each
ten shares of Common Stock issued and outstanding prior to the Second Reverse Split were converted into one share of Common Stock. The
Second Reverse Split became effective in the State of Delaware on July 16, 2024. All share amounts in these financial statements have
been updated for all periods presented to reflect the Second Reverse Split.&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000614"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000616"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000618"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000620"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000622">&lt;p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zac7UryYLn43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_821_zwl78hTbXRV3"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying condensed
financial statements have been prepared on the basis that the Company will continue as a going concern. As of October 31, 2024, the Company
had cash of $&lt;span id="xdx_90F_eus-gaap--Cash_iI_pn3n3_dm_c20241031_zINjqxEAtiQ2" title="Cash"&gt;4.1&lt;/span&gt; million, working capital of $&lt;span id="xdx_908_ecustom--WorkingCapitalDeficiency_iI_pn3n3_dm_c20241031_zrkiLXQ17Tp6" title="Working capital deficiency"&gt;3.5&lt;/span&gt; million, an accumulated deficit of $&lt;span id="xdx_900_eus-gaap--RetainedEarningsAppropriated_iI_pn3n3_dm_c20241031_zDXHJg9n0Hjj" title="Accumulated deficit"&gt;56.4&lt;/span&gt; million and stockholders&#x2019; equity of $&lt;span id="xdx_90D_eus-gaap--StockholdersEquityBeforeTreasuryStock_iI_pn3n3_dm_c20241031_zAz756civBq8" title="Stockholders' deficit"&gt;3.8&lt;/span&gt;
million. For the three and six months ended October 31, 2024, the Company had net losses of $&lt;span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_dm_c20240801__20241031_zXGoiTl1GVv8" title="Net loss"&gt;1.4&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_dm_c20240501__20241031_zsu2e8uj9LHi" title="Net loss"&gt;2.4&lt;/span&gt; million, respectively.
For the six months ended October 31, 2024, cash used in operating activities was $&lt;span id="xdx_906_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20240501__20241031_z8ryH7B5IG5l" title="Cash used in operating activities"&gt;4.5&lt;/span&gt; million. Historically, the Company has financed
its operations principally through issuances of equity and debt instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;Management
believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial
statements are issued. These factors create substantial doubt about the Company&#x2019;s ability to continue as a going concern for at
least one year after the date that these condensed financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s inability&#160;to
continue&#160;as a going concern&#160;could&#160;have a negative&#160;impact&#160;on the Company, including&#160;its ability&#160;to obtain
needed&#160;financing. The Company&#x2019;s condensed financial statements do not include any adjustments relating to the recoverability
and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should it be unable to
continue as a going concern.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company expects to continue
to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations
sufficient to fund its development and commercial operations. &lt;span style="background-color: white"&gt;These factors create substantial doubt
about our ability to continue as a going concern&lt;/span&gt;. However, based on the Company&#x2019;s current business plan, management believes
that the Company&#x2019;s cash and cash equivalents at October 31, 2024, together with the anticipated receipt of funds from its &#x201c;at-the-market&#x201d;
offering and from the sale of its Series A and Series B Convertible Preferred Stock pursuant to the securities purchase agreements related
thereto, will be sufficient to meet the Company&#x2019;s anticipated cash requirements during the twelve-month period subsequent to the
issuance of the financial statements included in this Quarterly Report.&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2024-10-31"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">4100000</us-gaap:Cash>
    <alzm:WorkingCapitalDeficiency
      contextRef="AsOf2024-10-31"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">3500000</alzm:WorkingCapitalDeficiency>
    <us-gaap:RetainedEarningsAppropriated
      contextRef="AsOf2024-10-31"
      decimals="-3"
      id="Fact000628"
      unitRef="USD">56400000</us-gaap:RetainedEarningsAppropriated>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="AsOf2024-10-31"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">3800000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-08-012024-10-31"
      decimals="-3"
      id="Fact000632"
      unitRef="USD">1400000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-05-01to2024-10-31"
      decimals="-3"
      id="Fact000634"
      unitRef="USD">2400000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <alzm:CashUsedInOperatingActivities
      contextRef="From2024-05-01to2024-10-31"
      decimals="-3"
      id="Fact000636"
      unitRef="USD">4500000</alzm:CashUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000639">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zuxoWxAHpn6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_820_zFfFfAnYehXh"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zI5HUlyECXMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zexHZ2PszJk8"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and the rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) applicable to interim
reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the
audited financial statements and notes thereto contained in the Company&#x2019;s Report on Form 10-K for the year ended April 30, 2024,
filed with the SEC on July 30, 2024. In the opinion of management, the accompanying condensed interim financial statements include all
adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods
are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed
financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent
fiscal year as reported in the Company&#x2019;s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April
30, 2024 has been derived from the audited balance sheet at April 30, 2024 contained in such Form 10-K.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zGb9vUnsiA07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zMK0CxrxZTnj"&gt;Accounting Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"&gt;The preparation of condensed
financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the
reported amounts of expenses during the reporting period. The Company&#x2019;s significant accounting policies that involve significant
judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could
differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCHZ7HOoD9qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zmyOiZRjh92k"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of October 31, 2024
and April&#160;30, 2024, the Company had &lt;span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20241031_zVxBAZTgmwR7" title="Cash equivalents"&gt;&lt;span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240430_zOP3iumdKFo3" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6rfn6VniW7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z80mgJptOpGk"&gt;Fair Value of Financial
Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 1: Quoted prices in
active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of warrants
are determined using the Black-Scholes valuation model, a &#x201c;Level 3&#x201d; fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the warrants and the risk free interest
rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants&#x2019; contractual life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSWl713MMOh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z5uJjqPqbjbl"&gt;Property and Equipment,
Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment
are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful life of &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241031_zZ1Bz5MlNSe8" style="display: none" title="Property and equipment estimated useful life"&gt;5&lt;/span&gt; five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to
expense as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zC6feYyBiWS6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zcWhotdCxx47"&gt;Research and Development
Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies,
as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses,
provided that there is no alternative future use of the rights in other research and development projects.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zAg1t59o3Ecc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z4diSl0PliNe"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#x2019;s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes stock-based
compensation expense for restricted stock units on a straight-line basis over the requisite service period and account for forfeitures
as they occur. The Company&#x2019;s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common
Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company&#x2019;s stock-based compensation could be materially different.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ExtendedProductWarrantyPolicy_zIdQEh3Qk1g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zCCyyJ0RIIj4"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with FASB ASC 480,&#160;&lt;i&gt;Distinguishing
Liabilities from Equity &lt;/i&gt;and FASB ASC 815,&#160;&lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;)&lt;i&gt;,&lt;/i&gt;&#160;depending on the
specific terms of the warrant agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Based on the terms of the
Company&#x2019;s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common
Stock, required settlement in shares and would be classified as equity under ASC 815.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z7zvXAL8dX0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z1eYNnG1UOWl"&gt;Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company utilizes FASB
ASC 260,&#160;&lt;i&gt;Earnings per Share&lt;/i&gt;. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Since the effects of outstanding
stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these
instruments have been excluded from the computation of loss per common share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following sets forth the
number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from
the computation of loss per common share:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBRnsDVzJUd1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zaUizIxtYFC3" style="display: none"&gt;Schedule of antidilutive securities excluded from computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Six Months Ended October 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zPOP5Pop3Wgd" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;116,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_z8xDxcJcqcu1" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;121,054&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;873,450&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;67,665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;990,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;188,969&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td id="xdx_F08_zhPkSTcw221e" style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td id="xdx_F1B_zFMTdC2STNK5" style="text-align: justify"&gt;The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with
an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per
share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB
ASC 260-10-45-14.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AA_zcfCEBWffJil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLkkA8l7RYBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zMON9y32hu3f"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company&#x2019;s financial position
or results of operations upon adoption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
condensed financial statements.&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000641">&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zI5HUlyECXMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zexHZ2PszJk8"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and the rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) applicable to interim
reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the
audited financial statements and notes thereto contained in the Company&#x2019;s Report on Form 10-K for the year ended April 30, 2024,
filed with the SEC on July 30, 2024. In the opinion of management, the accompanying condensed interim financial statements include all
adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods
are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed
financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent
fiscal year as reported in the Company&#x2019;s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April
30, 2024 has been derived from the audited balance sheet at April 30, 2024 contained in such Form 10-K.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-05-01to2024-10-31" id="Fact000643">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zGb9vUnsiA07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zMK0CxrxZTnj"&gt;Accounting Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"&gt;The preparation of condensed
financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the
reported amounts of expenses during the reporting period. The Company&#x2019;s significant accounting policies that involve significant
judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could
differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000645">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCHZ7HOoD9qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zmyOiZRjh92k"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of October 31, 2024
and April&#160;30, 2024, the Company had &lt;span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20241031_zVxBAZTgmwR7" title="Cash equivalents"&gt;&lt;span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240430_zOP3iumdKFo3" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000647"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000649"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-05-01to2024-10-31" id="Fact000651">&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6rfn6VniW7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z80mgJptOpGk"&gt;Fair Value of Financial
Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 1: Quoted prices in
active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of warrants
are determined using the Black-Scholes valuation model, a &#x201c;Level 3&#x201d; fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the warrants and the risk free interest
rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants&#x2019; contractual life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000654">&lt;p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSWl713MMOh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z5uJjqPqbjbl"&gt;Property and Equipment,
Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment
are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful life of &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241031_zZ1Bz5MlNSe8" style="display: none" title="Property and equipment estimated useful life"&gt;5&lt;/span&gt; five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to
expense as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2024-10-31" id="Fact000656">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-05-01to2024-10-31" id="Fact000658">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zC6feYyBiWS6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zcWhotdCxx47"&gt;Research and Development
Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies,
as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses,
provided that there is no alternative future use of the rights in other research and development projects.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-05-01to2024-10-31" id="Fact000660">&lt;p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zAg1t59o3Ecc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z4diSl0PliNe"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#x2019;s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes stock-based
compensation expense for restricted stock units on a straight-line basis over the requisite service period and account for forfeitures
as they occur. The Company&#x2019;s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common
Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company&#x2019;s stock-based compensation could be materially different.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ExtendedProductWarrantyPolicy contextRef="From2024-05-01to2024-10-31" id="Fact000662">&lt;p id="xdx_84D_eus-gaap--ExtendedProductWarrantyPolicy_zIdQEh3Qk1g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zCCyyJ0RIIj4"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with FASB ASC 480,&#160;&lt;i&gt;Distinguishing
Liabilities from Equity &lt;/i&gt;and FASB ASC 815,&#160;&lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;)&lt;i&gt;,&lt;/i&gt;&#160;depending on the
specific terms of the warrant agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Based on the terms of the
Company&#x2019;s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common
Stock, required settlement in shares and would be classified as equity under ASC 815.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ExtendedProductWarrantyPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000664">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z7zvXAL8dX0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z1eYNnG1UOWl"&gt;Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company utilizes FASB
ASC 260,&#160;&lt;i&gt;Earnings per Share&lt;/i&gt;. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Since the effects of outstanding
stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these
instruments have been excluded from the computation of loss per common share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following sets forth the
number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from
the computation of loss per common share:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBRnsDVzJUd1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zaUizIxtYFC3" style="display: none"&gt;Schedule of antidilutive securities excluded from computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Six Months Ended October 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zPOP5Pop3Wgd" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;116,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_z8xDxcJcqcu1" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;121,054&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;873,450&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;67,665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;990,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;188,969&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td id="xdx_F08_zhPkSTcw221e" style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td id="xdx_F1B_zFMTdC2STNK5" style="text-align: justify"&gt;The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with
an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per
share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB
ASC 260-10-45-14.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AA_zcfCEBWffJil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000667">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBRnsDVzJUd1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zaUizIxtYFC3" style="display: none"&gt;Schedule of antidilutive securities excluded from computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Six Months Ended October 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zPOP5Pop3Wgd" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;116,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_z8xDxcJcqcu1" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;121,054&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;873,450&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;67,665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;990,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;188,969&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td id="xdx_F08_zhPkSTcw221e" style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td id="xdx_F1B_zFMTdC2STNK5" style="text-align: justify"&gt;The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with
an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per
share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB
ASC 260-10-45-14.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-05-012024-10-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000669"
      unitRef="Shares">116999</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-05-012023-10-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000671"
      unitRef="Shares">121054</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-05-012024-10-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000673"
      unitRef="Shares">84</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-05-012023-10-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000675"
      unitRef="Shares">250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-05-012024-10-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000677"
      unitRef="Shares">873450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-05-012023-10-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000679"
      unitRef="Shares">67665</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">990533</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-05-012023-10-31"
      decimals="INF"
      id="Fact000683"
      unitRef="Shares">188969</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000686">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLkkA8l7RYBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zMON9y32hu3f"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company&#x2019;s financial position
or results of operations upon adoption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
condensed financial statements.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000688">&lt;p id="xdx_800_eus-gaap--OtherCurrentAssetsTextBlock_z2EtFPlEccxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&lt;span id="xdx_825_zHH1QrwUi9Vd"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prepaid expenses and other
current assets were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zp6360GtyP1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_zKCDdLZC6ae3" style="display: none"&gt;Schedule of prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241031_zrBnMf9ZLoHl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240430_zfxVdxEKjD01" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;April 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaidClinicalTrialExpenses_iI_pp0p0_maPEAOAzUiy_zu4y3rJcxvI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prepaid clinical trial expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;490,911&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzUiy_zruKMZL2rvCj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;163,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzUiy_zGjojI8b7Tn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;19,426&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,671&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0p0_mtPEAOAzUiy_z82835lwKRN2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;673,669&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;79,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 22, 2024, the Company
entered into a Study Start-up Agreement with Massachusetts General Hospital (&#x201c;Mass General Agreement&#x201d;) in preparation for
five clinical research trials for its AL001 product candidate. The Mass General Agreement required a prepayment of $&lt;span id="xdx_904_ecustom--PrepaidClinicalTrialFees_c20241022__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Prepaid clinical trial fees"&gt;514,000&lt;/span&gt;. Prepaid clinical
trial expenses at October 31, 2024 represented the unamortized portion of clinical trial expense and will be amortized as used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 14, 2024, the Company
purchased directors&#x2019; and officers&#x2019; insurance for 12 months in the amount of $&lt;span id="xdx_90E_ecustom--InsurancePurchased_iI_pp0p0_c20240614__srt--TitleOfIndividualAxis__us-gaap--DirectorsAndOfficersLiabilityInsuranceMember_zdF59KZLaYpc" title="Insurance purchased"&gt;227,000&lt;/span&gt;. Prepaid insurance at October 31, 2024
represented the unamortized portion of directors&#x2019; and officers&#x2019; insurance.&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000690">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zp6360GtyP1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_zKCDdLZC6ae3" style="display: none"&gt;Schedule of prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241031_zrBnMf9ZLoHl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240430_zfxVdxEKjD01" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;April 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaidClinicalTrialExpenses_iI_pp0p0_maPEAOAzUiy_zu4y3rJcxvI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prepaid clinical trial expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;490,911&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzUiy_zruKMZL2rvCj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;163,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzUiy_zGjojI8b7Tn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;19,426&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,671&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0p0_mtPEAOAzUiy_z82835lwKRN2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;673,669&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;79,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <alzm:PrepaidClinicalTrialExpenses
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000692"
      unitRef="USD">490911</alzm:PrepaidClinicalTrialExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000695"
      unitRef="USD">163332</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000696"
      unitRef="USD">60523</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000698"
      unitRef="USD">19426</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000699"
      unitRef="USD">18671</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000701"
      unitRef="USD">673669</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000702"
      unitRef="USD">79194</us-gaap:PrepaidExpenseAndOtherAssets>
    <alzm:PrepaidClinicalTrialFees
      contextRef="AsOf2024-10-22_custom_AL001LicenseMember"
      decimals="0"
      id="Fact000704"
      unitRef="USD">514000</alzm:PrepaidClinicalTrialFees>
    <alzm:InsurancePurchased
      contextRef="AsOf2024-06-14_us-gaap_DirectorsAndOfficersLiabilityInsuranceMember"
      decimals="0"
      id="Fact000706"
      unitRef="USD">227000</alzm:InsurancePurchased>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000708">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zJ3OqgLXNDZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_828_zwjwx94Tq5la"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;2016 Stock Incentive
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 30, 2016, the Company&#x2019;s
stockholders approved the Company&#x2019;s 2016 Stock Incentive Plan (the &#x201c;Plan&#x201d;). The Plan provides for the issuance of a
maximum of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_pdd" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;83,333&lt;/span&gt; shares of Common Stock to be offered to the Company&#x2019;s directors, officers, employees, and consultants. On March
1, 2019, the Company&#x2019;s stockholders approved an additional &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190228__20190301__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_pdd" title="Share-based compensation arrangement by share-based payment award, number of additional shares authorized"&gt;50,000&lt;/span&gt; shares to be available for issuance under the Plan. Options granted
under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and
become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20160429__20160430__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_z6cq1NAsXZse" title="Share-based compensation arrangement by share-based payment award, expiration period"&gt;10&lt;/span&gt; years from the
date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;2021 Stock Incentive
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In February 2021, the Company&#x2019;s
board of directors (the &#x201c;Board&#x201d;) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan
(the &#x201c;2021 Plan&#x201d;). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory),
(2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Stock Subject to the 2021
Plan.&lt;/i&gt;&#160;The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 66,667 shares, which number will
be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as otherwise
provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange
for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires
or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant
under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the
2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Restricted Stock.&lt;/i&gt; In
May 2021, the Company issued restricted stock awards pursuant to the 2021 Plan to one employee. The restricted stock award vests over
48 months. The award requires continued service to the Company during the vesting period. The vesting provisions of individual awards
may vary as approved by the Board. Compensation expense for restricted stock is generally recorded based on its market value on the date
of grant and recognized ratably over the associated service and performance period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Stock Options.&lt;/i&gt; All
options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms
of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the
date of issuance of these options, there was not an active public market for the Company&#x2019;s shares. Accordingly, the fair value of
the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products
and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available
on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method.
The expected life of the options used was based on the contractual life calculated using the simplified method. Stock-based compensation
is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead
of settling such obligations with cash payments.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A summary of stock option
activity for the six months ended October 31, 2024 is presented below:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVctCE3A4dBc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zEzYp3UcWpCb" style="display: none"&gt;Schedule of share-based payment arrangement, option, activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Outstanding Options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Shares &lt;br/&gt; Available &lt;br/&gt; for Grant&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Number of &lt;br/&gt; Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life (years)&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic &lt;br/&gt; Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance at April 30, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20240501__20241031_zZ4U65rAVeEf" style="width: 9%; text-align: right" title="Shares available for grant begining (in shares)"&gt;62,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240501__20241031_zIgJcQ3hI435" style="width: 9%; text-align: right" title="Number of shares begining (in shares)"&gt;98,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240501__20241031_zxhtTdR9bZZg" style="width: 9%; text-align: right" title="Weighted average exercise price begining (in dollars per share)"&gt;178.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20241031_z00GzKlfDCza" style="width: 9%; text-align: right" title="Weighted average remaining contractual life begining (years)"&gt;5.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240501__20241031_zshmCgIsHPWj" style="width: 9%; text-align: right" title="Aggregate intrinsic value begining"&gt;70,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SharesAvailableForGrantOptionsGranted_c20240501__20241031_pdd" style="text-align: right" title="Shares available for grant, Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0729"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240501__20241031_pdd" style="text-align: right" title="Number of shares, Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="text-align: right" title="Weighted average exercise price, Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharesAvailableForGrantOptionsExercised_c20240501__20241031_pdd" style="text-align: right" title="Shares available for grant, Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240501__20241031_pdd" style="text-align: right" title="Number of shares, Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="text-align: right" title="Weighted average exercise price, Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharesAvailableForGrantOptionsExpired_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Options expired"&gt;3,333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240501__20241031_z9XsCqWFMKIa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Options expired"&gt;(3,333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Options expired"&gt;150.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20240501__20241031_zN1Txv3U3hPd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant end (in shares)"&gt;65,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240501__20241031_zxf8EEBPqtt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares end (in shares)"&gt;94,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240501__20241031_z119PtSMDeBf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price end (in dollars per share)"&gt;179.11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240501__20241031_z9iracl22JH4" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life end (years)"&gt;4.90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240501__20241031_zN4BreSfmOO7" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value end"&gt;15,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options vested and expected to vest at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest at end"&gt;88,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20241031_pdd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Options vested and expected to vest at end"&gt;179.39&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240501__20241031_zqQk6vqYePka" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life, Options vested and expected to vest at end"&gt;4.65&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20241031_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Options vested and expected to vest at end"&gt;15,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable at end"&gt;87,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20241031_pdd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Options exercisable at end"&gt;178.87&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240501__20241031_zNNf3Nqwstkh" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life, Options exercisable at end"&gt;4.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20241031_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Options exercisable at end"&gt;15,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zIn33yELNdSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The aggregate intrinsic value
in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective
date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised
their options.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted stock unit activity
for the six months ended October 31, 2024 is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zSiEgKzV0rhd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zGqDd9BGUwC3" style="display: none"&gt;Schedule of nonvested restricted stock units activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 63%; text-align: left"&gt;Unvested at April 30, 2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240501__20241031_znAntT7Wjie1" style="width: 15%; text-align: right" title="Unvested shares, Beginning balance"&gt;167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240501__20241031_z4MomUlexUCk" style="width: 15%; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Beginning balance"&gt;375.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240501__20241031_pdd" style="text-align: right" title="Unvested shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" style="text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240501__20241031_pdd" style="text-align: right" title="Unvested shares, Vested"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" style="text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Vested"&gt;375.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested shares, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0788"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Unvested at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240501__20241031_zw3UdzQE05Nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested shares, Ending balance"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240501__20241031_zD4MSBxQMKwk" style="padding-bottom: 2.5pt; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Ending balance"&gt;375.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z7rL5KUS3TE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Performance Contingent
Stock Options Granted to Employee&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On November 26, 2019, the
Board granted &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_pdd" title="Options granted"&gt;28,333&lt;/span&gt; performance and market contingent awards to certain key employees and a director. These grants were made outside
of the Plan. These awards have an exercise price of $225.00 per share. These awards have multiple separate market triggers for vesting
based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive
trading days later than 180 days after the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) for its common stock, or (ii) stepped
target prices for a change in control transaction. The target prices ranged from $1,500 per share to $6,000 per share. &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember" title="Terms of award"&gt;In the event any
of the stock price milestones are not achieved within three years&lt;/span&gt;, the unvested portion of the performance options will be reduced by
25%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On November 22, 2022, the
Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $1,500 per share
to $3,000 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three
years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties
associated with achieving the market-contingent awards, as of October 31, 2024, management believes that the achievement of the requisite
performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On November 29, 2022, the
Compensation Committee of the Board granted 13,333 performance-based stock option to the Chief Executive Officer at an exercise price
of $175.50 per share, of which 50% vest upon the completion and announcement of topline data from the Company&#x2019;s Phase II clinical
trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from
the Company&#x2019;s Phase II clinical trial of ALZN002 within four years from the grant date. During the three months ended July 31, 2023,
management believed that it was probable that the performance condition of the completion and announcement of topline data from the Company&#x2019;s
Phase II clinical trial of AL001 would be achieved and had recognized the related stock-based compensation. As of October 31, 2024, management
believed that the achievement of the second performance condition was not probable and, as a result, no compensation cost has been recognized
related to Phase I/IIA of ALZN002.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Performance Contingent
Stock Options Granted to TAMM Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 23, 2021, the Company
issued performance-based stock options to certain team members at TAMM Net, Inc. (&#x201c;TAMM Net&#x201d;) to purchase an aggregate of
3,000 shares of Common Stock at a per share exercise price of $225.00 per share, of which 50% would vest upon the completion of Phase
I of AL001 by March 31, 2022, and the remaining 50% would vest upon completion of Phase I/IIA of ALZN002 by December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On January 19, 2023, the Board
modified the performance criteria for these awards. The remaining 50% of the grant will now vest upon the completion and announcement
of topline data of the first cohort from a Phase I/IIA clinical trial of ALZN002 on/or before March 31, 2024. The modified performance
criteria was not met on or before March 31, 2024 and, as a result, the remaining unvested stock options were cancelled and no compensation
cost has been recognized for these awards related to ALZN002.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Performance Contingent
Stock Options Granted to Consultants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 14, 2021, the Company
issued performance-based stock options to two consultants to purchase an aggregate of 1,334 shares of Common Stock with an exercise price
of $363.00 per share, of which 333 vest upon completion of each of the Phase II clinical trials of AL001 for a BD indication, AL001 for
a PTSD indication, AL001 for an MDD indication and ALZN002 for an Alzheimer&#x2019;s indication.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On January 19, 2023, the Board
modified the performance criteria for these awards. The revised grant will vest 25% if the Company (a) completes and announces topline
data from a Phase II clinical trial of AL001 and ALZN002, as applicable, that would support a new drug application for the drug candidate
and the indication listed below, and (b) obtained a &#x201c;Study May Proceed&#x201d; letter from the U.S. Food and Drug Administration
(&#x201c;FDA&#x201d;) for the additional Investigational New Drug (&#x201c;IND&#x201d;) on/or before December 31, 2023, as follows: (i) AL001
&#x2013; BD; (ii) AL001- MDD; (iii) AL001 &#x2013; PTSD; and (iv) ALZN002 &#x2013; Alzheimer&#x2019;s.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended April
30, 2024, the Company filed INDs for BD, MDD and PTSD and received a &#x201c;Study May Proceed&#x201d; letter for BD in October 2023, MDD
in November 2023 and PTSD in December 2023. As a result, 75% of the performance grant vested and the Company recognized stock-based compensation
related to the vesting. As of October 31, 2024, management believed that the achievement of the remaining requisite performance condition
was not probable and, as a result, no compensation cost has been recognized for these awards related to ALZN002 &#x2013; Alzheimer&#x2019;s.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation
Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s results
of operations included expenses relating to stock-based compensation for three and six months ended October 31, 2024 and 2023, were comprised
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zt1KAqdUZDv" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B1_zS70DLh5jzc7" style="display: none"&gt;Schedule of stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended October 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Six Months Ended October 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;&#160;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total"&gt;142,603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;81,277&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;175,733&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;162,554&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;545,113&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;81,277&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;175,733&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;162,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;687,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zVAT2YRkOVUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of October 31, 2024, total
unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20241031__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_pp0p0" title="Unamortized stock-based compensation expense related to unvested employee and non-employee awards"&gt;284,000&lt;/span&gt;.
The weighted-average period over which such stock-based compensation expense will be recognized was approximately &lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8nrVfS0hDqk" title="Weighted-average period"&gt;0.9&lt;/span&gt; years.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-04-30_custom_StockIncentivePlan2016Member"
      decimals="INF"
      id="Fact000710"
      unitRef="Shares">83333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2019-02-282019-03-01_custom_StockIncentivePlan2016Member"
      decimals="INF"
      id="Fact000712"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2016-04-292016-04-30_srt_MaximumMember_custom_StockIncentivePlan2016Member"
      id="Fact000714">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000717">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVctCE3A4dBc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zEzYp3UcWpCb" style="display: none"&gt;Schedule of share-based payment arrangement, option, activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Outstanding Options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Shares &lt;br/&gt; Available &lt;br/&gt; for Grant&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Number of &lt;br/&gt; Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life (years)&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic &lt;br/&gt; Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance at April 30, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20240501__20241031_zZ4U65rAVeEf" style="width: 9%; text-align: right" title="Shares available for grant begining (in shares)"&gt;62,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240501__20241031_zIgJcQ3hI435" style="width: 9%; text-align: right" title="Number of shares begining (in shares)"&gt;98,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240501__20241031_zxhtTdR9bZZg" style="width: 9%; text-align: right" title="Weighted average exercise price begining (in dollars per share)"&gt;178.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20241031_z00GzKlfDCza" style="width: 9%; text-align: right" title="Weighted average remaining contractual life begining (years)"&gt;5.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240501__20241031_zshmCgIsHPWj" style="width: 9%; text-align: right" title="Aggregate intrinsic value begining"&gt;70,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SharesAvailableForGrantOptionsGranted_c20240501__20241031_pdd" style="text-align: right" title="Shares available for grant, Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0729"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240501__20241031_pdd" style="text-align: right" title="Number of shares, Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="text-align: right" title="Weighted average exercise price, Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharesAvailableForGrantOptionsExercised_c20240501__20241031_pdd" style="text-align: right" title="Shares available for grant, Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240501__20241031_pdd" style="text-align: right" title="Number of shares, Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="text-align: right" title="Weighted average exercise price, Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharesAvailableForGrantOptionsExpired_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Options expired"&gt;3,333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240501__20241031_z9XsCqWFMKIa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Options expired"&gt;(3,333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Options expired"&gt;150.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20240501__20241031_zN1Txv3U3hPd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant end (in shares)"&gt;65,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240501__20241031_zxf8EEBPqtt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares end (in shares)"&gt;94,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240501__20241031_z119PtSMDeBf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price end (in dollars per share)"&gt;179.11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240501__20241031_z9iracl22JH4" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life end (years)"&gt;4.90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240501__20241031_zN4BreSfmOO7" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value end"&gt;15,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options vested and expected to vest at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest at end"&gt;88,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20241031_pdd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Options vested and expected to vest at end"&gt;179.39&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240501__20241031_zqQk6vqYePka" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life, Options vested and expected to vest at end"&gt;4.65&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20241031_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Options vested and expected to vest at end"&gt;15,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241031_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable at end"&gt;87,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20241031_pdd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Options exercisable at end"&gt;178.87&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240501__20241031_zNNf3Nqwstkh" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average remaining contractual life, Options exercisable at end"&gt;4.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20241031_pp0p0" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, Options exercisable at end"&gt;15,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000719"
      unitRef="Shares">62000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">98000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000723"
      unitRef="USDPShares">178.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-05-01to2024-10-31" id="Fact000725">P5Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000727"
      unitRef="USD">70500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <alzm:SharesAvailableForGrantOptionsExpired
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000741"
      unitRef="Shares">3333</alzm:SharesAvailableForGrantOptionsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">3333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000745"
      unitRef="USDPShares">150.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000747"
      unitRef="Shares">65333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000749"
      unitRef="Shares">94667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000751"
      unitRef="USDPShares">179.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <alzm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2024-05-01to2024-10-31" id="Fact000753">P4Y10M24D</alzm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">15100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000757"
      unitRef="Shares">88001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000759"
      unitRef="USDPShares">179.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2024-05-01to2024-10-31" id="Fact000761">P4Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000763"
      unitRef="USD">15100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000765"
      unitRef="Shares">87043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000767"
      unitRef="USDPShares">178.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-05-01to2024-10-31" id="Fact000769">P4Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000771"
      unitRef="USD">15100</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000774">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zSiEgKzV0rhd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zGqDd9BGUwC3" style="display: none"&gt;Schedule of nonvested restricted stock units activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 63%; text-align: left"&gt;Unvested at April 30, 2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240501__20241031_znAntT7Wjie1" style="width: 15%; text-align: right" title="Unvested shares, Beginning balance"&gt;167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240501__20241031_z4MomUlexUCk" style="width: 15%; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Beginning balance"&gt;375.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240501__20241031_pdd" style="text-align: right" title="Unvested shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" style="text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240501__20241031_pdd" style="text-align: right" title="Unvested shares, Vested"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" style="text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Vested"&gt;375.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested shares, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0788"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Unvested at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240501__20241031_zw3UdzQE05Nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested shares, Ending balance"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240501__20241031_zD4MSBxQMKwk" style="padding-bottom: 2.5pt; text-align: right" title="Unvested Weighted Average Grant Date Fair Value, Ending balance"&gt;375.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000778"
      unitRef="USDPShares">375.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000784"
      unitRef="Shares">83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000786"
      unitRef="USDPShares">375.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000792"
      unitRef="Shares">84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000794"
      unitRef="USDPShares">375.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember"
      decimals="INF"
      id="Fact000796"
      unitRef="Shares">28333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember"
      id="Fact000798">In the event any
of the stock price milestones are not achieved within three years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000801">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zt1KAqdUZDv" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B1_zS70DLh5jzc7" style="display: none"&gt;Schedule of stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended October 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Six Months Ended October 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;&#160;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total"&gt;142,603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;81,277&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;175,733&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;162,554&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;545,113&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;81,277&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;175,733&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;162,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;687,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-05-012023-10-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000809"
      unitRef="USD">142603</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-08-012024-10-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000811"
      unitRef="USD">81277</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-08-012023-10-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000813"
      unitRef="USD">175733</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-05-012024-10-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000815"
      unitRef="USD">162554</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-05-012023-10-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000817"
      unitRef="USD">545113</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000819"
      unitRef="USD">81277</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-08-012023-10-31"
      decimals="0"
      id="Fact000821"
      unitRef="USD">175733</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact000823"
      unitRef="USD">162554</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-05-012023-10-31"
      decimals="0"
      id="Fact000825"
      unitRef="USD">687716</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-10-31_custom_UnamortizedStockBasedCompensationMember"
      decimals="0"
      id="Fact000827"
      unitRef="USD">284000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-05-012024-10-31_custom_StockBasedCompensationMember"
      id="Fact000829">P0Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000831">&lt;p id="xdx_80B_eus-gaap--ProductWarrantyDisclosureTextBlock_zL13sjSHx1oj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_821_z8aPZFuoCxta"&gt;WARRANTS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three months ended
October 31, 2024, the Company issued warrants to purchase an aggregate of &lt;span id="xdx_902_ecustom--AggregateNumberOfStockRepurchase_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Aggregate number of stock repurchase"&gt;440,000&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)"&gt;12.50&lt;/span&gt;
per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 36pt"&gt;&lt;/td&gt;&lt;td style="width: 22.45pt"&gt;(i)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On August 19, 2024, the Company issued a warrant to purchase &lt;span id="xdx_903_ecustom--AggregateNumberOfStockRepurchase_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Aggregate number of stock repurchase"&gt;160,000&lt;/span&gt; shares of Common Stock at an exercise
price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)"&gt;12.50&lt;/span&gt; in connection with the sale of convertible preferred stock to Orchid Finance, LLC (&#x201c;Orchid&#x201d;) for $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zN6ksDfyqfu5" title="Value of common stock sold"&gt;2,000,000&lt;/span&gt;.
Based on the terms of the Company&#x2019;s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant
is indexed to the common stock, requires settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant
on the date issued was $&lt;span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zDhYlazCUQU9" title="Fair value of warrant"&gt;571,000&lt;/span&gt;.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 36pt"&gt;&lt;/td&gt;&lt;td style="width: 22.5pt"&gt;(ii)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On August 21, 2024, the Company issued a warrant to purchase &lt;span id="xdx_908_ecustom--AggregateNumberOfStockRepurchase_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Aggregate number of stock repurchase"&gt;200,000&lt;/span&gt; shares of Common Stock at an exercise
price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)"&gt;12.50&lt;/span&gt; in connection with the sale of convertible preferred stock to Orchid for $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zRzvjrNAi55d" title="Value of common stock sold"&gt;2,500,000&lt;/span&gt;. Based on the terms of the Company&#x2019;s
warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires
settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zY1ynwDN0Kkd" title="Fair value of warrant"&gt;486,000&lt;/span&gt;.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -22.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 36pt"&gt;&lt;/td&gt;&lt;td style="width: 22.5pt"&gt;(iii)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On September 11, 2024, the Company issued a warrant to purchase &lt;span id="xdx_909_ecustom--AggregateNumberOfStockRepurchase_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Aggregate number of stock repurchase"&gt;80,000&lt;/span&gt; shares of Common Stock at an exercise
price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)"&gt;12.50&lt;/span&gt; in connection with the sale of convertible preferred stock to Orchid for $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zTmwf9omOlG" title="Value of common stock sold"&gt;1,000,000&lt;/span&gt;. Based on the terms of the Company&#x2019;s
warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires
settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zaBfIB7ZJSa8" title="Fair value of warrant"&gt;69,000&lt;/span&gt;.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrant activity for the six
months ended October 31, 2024 is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantActivityTableTextBlock_zWMLNR3BTmk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B1_zRpP47Cprvm9" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at April 30, 2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240501__20241031_zF0F44KaE1Gl" style="width: 15%; text-align: right" title="Class of warrant or right, outstanding, beginning"&gt;240,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240501__20241031_zZ8SJdEkcPK1" style="width: 15%; text-align: center" title="Weighted average exercise price, beginning"&gt;$67.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20240501__20241031_pdd" style="text-align: right" title="Class of warrant or right, outstanding, granted"&gt;640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--WeightedAverageExercisesPriceGranted_c20240501__20241031_pdd" style="text-align: center" title="Weighted average exercise price, granted"&gt;$12.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingCancelledexpired_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Class of warrant or right, outstanding, cancelled/expired"&gt;(6,999&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--WeightedAverageExercisePriceCancelledexpired_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: center" title="Weighted average exercise price, cancelled/expired"&gt;$320.28&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Outstanding at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240501__20241031_z2Cy4zu45xT" style="border-bottom: Black 2.5pt double; text-align: right" title="Class of warrant or right, outstanding, ending"&gt;873,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240501__20241031_zdJEUTA9lwr7" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average exercise price, ending"&gt;$24.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_znTKJxjjQW84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes
information about Common Stock warrants outstanding and exercisable at October 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z6sfzHeW9Gh8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - WARRANTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&lt;span id="xdx_8B4_z6R1aopOG5wb" style="display: none"&gt;Schedule of common stock warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 15%; text-align: center"&gt;$&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)"&gt;12.00&lt;/span&gt;-$&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)"&gt;12.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Class of Warrant or Right, Outstanding"&gt;850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zI8Z94sjgH3j" title="Weighted average remaining contractual life (years)"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;12.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Number of warrant exercisable"&gt;850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;12.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Exercse price (in dollars per share)"&gt;450.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Class of Warrant or Right, Outstanding"&gt;23,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zq9JReh6gzxb" title="Weighted average remaining contractual life (years)"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;450.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Number of warrant exercisable"&gt;23,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;450.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;$&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Exercse price (in dollars per share)"&gt;937.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Class of Warrant or Right, Outstanding"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_z8IiHBUXHcZd" title="Weighted average remaining contractual life (years)"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;937.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrant exercisable"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;937.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)"&gt;12.00&lt;/span&gt; - $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)"&gt;937.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_zIQihYGkCStb" title="Class of Warrant or Right, Outstanding"&gt;873,450&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_zT1TcctG5qy9" title="Weighted average remaining contractual life (years)"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;24.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrant exercisable"&gt;873,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;24.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ProductWarrantyDisclosureTextBlock>
    <alzm:AggregateNumberOfStockRepurchase
      contextRef="From2024-05-012024-10-31_custom_Warrant2024Member"
      decimals="INF"
      id="Fact000833"
      unitRef="Shares">440000</alzm:AggregateNumberOfStockRepurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-31_custom_Warrant2024Member"
      decimals="INF"
      id="Fact000835"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alzm:AggregateNumberOfStockRepurchase
      contextRef="From2024-08-012024-08-19_custom_Warrant2024Member"
      decimals="INF"
      id="Fact000837"
      unitRef="Shares">160000</alzm:AggregateNumberOfStockRepurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-19_custom_Warrant2024Member"
      decimals="INF"
      id="Fact000839"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-08-012024-08-19_custom_Warrant2024Member"
      decimals="0"
      id="Fact000841"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-08-012024-08-19_custom_Warrant2024Member"
      decimals="0"
      id="Fact000843"
      unitRef="USD">571000</us-gaap:FairValueAdjustmentOfWarrants>
    <alzm:AggregateNumberOfStockRepurchase
      contextRef="From2024-08-012024-08-21_custom_Warrant2024Member"
      decimals="INF"
      id="Fact000845"
      unitRef="Shares">200000</alzm:AggregateNumberOfStockRepurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-21_custom_Warrant2024Member"
      decimals="INF"
      id="Fact000847"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-08-012024-08-21_custom_Warrant2024Member"
      decimals="0"
      id="Fact000849"
      unitRef="USD">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-08-012024-08-21_custom_Warrant2024Member"
      decimals="0"
      id="Fact000851"
      unitRef="USD">486000</us-gaap:FairValueAdjustmentOfWarrants>
    <alzm:AggregateNumberOfStockRepurchase
      contextRef="From2024-09-012024-09-11_custom_Warrant2024Member"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">80000</alzm:AggregateNumberOfStockRepurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-11_custom_Warrant2024Member"
      decimals="INF"
      id="Fact000855"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-09-012024-09-11_custom_Warrant2024Member"
      decimals="0"
      id="Fact000857"
      unitRef="USD">1000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-09-012024-09-11_custom_Warrant2024Member"
      decimals="0"
      id="Fact000859"
      unitRef="USD">69000</us-gaap:FairValueAdjustmentOfWarrants>
    <alzm:ScheduleOfWarrantActivityTableTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000862">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantActivityTableTextBlock_zWMLNR3BTmk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B1_zRpP47Cprvm9" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at April 30, 2024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240501__20241031_zF0F44KaE1Gl" style="width: 15%; text-align: right" title="Class of warrant or right, outstanding, beginning"&gt;240,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240501__20241031_zZ8SJdEkcPK1" style="width: 15%; text-align: center" title="Weighted average exercise price, beginning"&gt;$67.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20240501__20241031_pdd" style="text-align: right" title="Class of warrant or right, outstanding, granted"&gt;640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--WeightedAverageExercisesPriceGranted_c20240501__20241031_pdd" style="text-align: center" title="Weighted average exercise price, granted"&gt;$12.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingCancelledexpired_c20240501__20241031_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Class of warrant or right, outstanding, cancelled/expired"&gt;(6,999&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--WeightedAverageExercisePriceCancelledexpired_c20240501__20241031_pdd" style="padding-bottom: 1pt; text-align: center" title="Weighted average exercise price, cancelled/expired"&gt;$320.28&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Outstanding at October 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240501__20241031_z2Cy4zu45xT" style="border-bottom: Black 2.5pt double; text-align: right" title="Class of warrant or right, outstanding, ending"&gt;873,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240501__20241031_zdJEUTA9lwr7" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average exercise price, ending"&gt;$24.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</alzm:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000864"
      unitRef="Shares">240449</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-30"
      decimals="INF"
      id="Fact000866"
      unitRef="USDPShares">67.45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alzm:ClassOfWarrantOrRightOutstandingGranted
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000868"
      unitRef="Shares">640000</alzm:ClassOfWarrantOrRightOutstandingGranted>
    <alzm:WeightedAverageExercisesPriceGranted
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000870"
      unitRef="USDPShares">12.50</alzm:WeightedAverageExercisesPriceGranted>
    <alzm:ClassOfWarrantOrRightOutstandingCancelledexpired
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000872"
      unitRef="Shares">-6999</alzm:ClassOfWarrantOrRightOutstandingCancelledexpired>
    <alzm:WeightedAverageExercisePriceCancelledexpired
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact000874"
      unitRef="USDPShares">320.28</alzm:WeightedAverageExercisePriceCancelledexpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000876"
      unitRef="Shares">873450</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact000878"
      unitRef="USDPShares">24.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000880">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z6sfzHeW9Gh8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - WARRANTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&lt;span id="xdx_8B4_z6R1aopOG5wb" style="display: none"&gt;Schedule of common stock warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 15%; text-align: center"&gt;$&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)"&gt;12.00&lt;/span&gt;-$&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)"&gt;12.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Class of Warrant or Right, Outstanding"&gt;850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zI8Z94sjgH3j" title="Weighted average remaining contractual life (years)"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;12.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Number of warrant exercisable"&gt;850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;12.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Exercse price (in dollars per share)"&gt;450.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Class of Warrant or Right, Outstanding"&gt;23,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zq9JReh6gzxb" title="Weighted average remaining contractual life (years)"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;450.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Number of warrant exercisable"&gt;23,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;450.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;$&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Exercse price (in dollars per share)"&gt;937.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Class of Warrant or Right, Outstanding"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_z8IiHBUXHcZd" title="Weighted average remaining contractual life (years)"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;937.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrant exercisable"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;937.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)"&gt;12.00&lt;/span&gt; - $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)"&gt;937.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_zIQihYGkCStb" title="Class of Warrant or Right, Outstanding"&gt;873,450&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_zT1TcctG5qy9" title="Weighted average remaining contractual life (years)"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;24.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrant exercisable"&gt;873,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;24.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-31_custom_ExercisePrice1Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000882"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-31_custom_ExercisePrice1Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000884"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-10-31_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000886"
      unitRef="Shares">850000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-10-31_custom_ExercisePrice1Member"
      id="Fact000888">P4Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <alzm:WarrantOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-10-31_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000890"
      unitRef="USDPShares">12.38</alzm:WarrantOutstandingWeightedAverageExercisePrice>
    <alzm:NumberOfWarrantExercisable
      contextRef="AsOf2024-10-31_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">850000</alzm:NumberOfWarrantExercisable>
    <alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare
      contextRef="AsOf2024-10-31_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">12.38</alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-31_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000896"
      unitRef="USDPShares">450.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-10-31_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000898"
      unitRef="Shares">23042</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-10-31_custom_ExercisePrice3Member"
      id="Fact000900">P1Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <alzm:WarrantOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-10-31_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000902"
      unitRef="USDPShares">450.00</alzm:WarrantOutstandingWeightedAverageExercisePrice>
    <alzm:NumberOfWarrantExercisable
      contextRef="AsOf2024-10-31_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000904"
      unitRef="Shares">23042</alzm:NumberOfWarrantExercisable>
    <alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare
      contextRef="AsOf2024-10-31_custom_ExercisePrice3Member"
      decimals="INF"
      id="Fact000906"
      unitRef="USDPShares">450.00</alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-31_custom_ExercisePrice4Member"
      decimals="INF"
      id="Fact000908"
      unitRef="USDPShares">937.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-10-31_custom_ExercisePrice4Member"
      decimals="INF"
      id="Fact000910"
      unitRef="Shares">408</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-10-31_custom_ExercisePrice4Member"
      id="Fact000912">P1Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <alzm:WarrantOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-10-31_custom_ExercisePrice4Member"
      decimals="INF"
      id="Fact000914"
      unitRef="USDPShares">937.50</alzm:WarrantOutstandingWeightedAverageExercisePrice>
    <alzm:NumberOfWarrantExercisable
      contextRef="AsOf2024-10-31_custom_ExercisePrice4Member"
      decimals="INF"
      id="Fact000916"
      unitRef="Shares">408</alzm:NumberOfWarrantExercisable>
    <alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare
      contextRef="AsOf2024-10-31_custom_ExercisePrice4Member"
      decimals="INF"
      id="Fact000918"
      unitRef="USDPShares">937.50</alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-31_custom_ExercisePrice5Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000920"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-31_custom_ExercisePrice5Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000922"
      unitRef="USDPShares">937.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-10-31_custom_ExercisePrice5Member"
      decimals="INF"
      id="Fact000924"
      unitRef="Shares">873450</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-10-31_custom_ExercisePrice5Member"
      id="Fact000926">P4Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <alzm:WarrantOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-10-31_custom_ExercisePrice5Member"
      decimals="INF"
      id="Fact000928"
      unitRef="USDPShares">24.35</alzm:WarrantOutstandingWeightedAverageExercisePrice>
    <alzm:NumberOfWarrantExercisable
      contextRef="AsOf2024-10-31_custom_ExercisePrice5Member"
      decimals="INF"
      id="Fact000930"
      unitRef="Shares">873450</alzm:NumberOfWarrantExercisable>
    <alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare
      contextRef="AsOf2024-10-31_custom_ExercisePrice5Member"
      decimals="INF"
      id="Fact000932"
      unitRef="USDPShares">24.35</alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000934">&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z44mI7QlzLbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_82D_z59Kh8pHSYMg"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Contractual Obligations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On
July 2, 2018, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and
its affiliate, the University of South Florida (the &#x201c;AL001 Licenses&#x201d;), pursuant to which the Licensor granted the Company
a royalty bearing exclusive worldwide licenses limited to the field of Alzheimer&#x2019;s, under United States Patent Nos. (i) 9,840,521,
entitled &#x201c;Organic Anion Lithium Ionic Cocrystal Compounds and Compositions&#x201d;, filed September 24, 2015 and granted December
12, 2017, and (ii) 9,603,869, entitled &#x201c;Lithium Co-Crystals for Treatment of Neuropsychiatric Disorders&#x201d;, filed May 21, 2016
and granted March 28, 2017. On February 1, 2019, the Company entered into the First Amendments to the AL001 Licenses, on March 30, 2021,
the Company entered into the Second Amendments to the AL001 Licenses and on June 8, 2023, the Company entered into the Third Amendments
to the AL001 Licenses (collectively, the &#x201c;AL001 License Agreements&#x201d;). The Third Amendments to the AL001 Licenses modified
the timing of the payments of the license fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
AL001 License Agreements require that the Company pay combined royalty payments of&#160;&lt;span id="xdx_906_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pdd" title="Percentage of royalty payments on net sales of product"&gt;4.5%&lt;/span&gt;&#160;on net sales of products developed from
the licensed technology for AL001.&#160;&lt;span id="xdx_90D_ecustom--DescriptionOfLicensesAgreements_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Description of licenses agreements"&gt;The Company has already paid an initial license fee of $&lt;span id="xdx_903_ecustom--InitialLicenseFees_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Initial license fees"&gt;200,000&lt;/span&gt;&#160;for AL001. As an additional
licensing fee for the license of the AL001 technologies, the Licensor received&#160;14,853 shares of Common Stock. Minimum royalties for
AL001 License Agreements are $&lt;span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p0" title="Payments for royalties"&gt;40,000&lt;/span&gt;&#160;on the first anniversary of the first commercial sale, $&lt;span id="xdx_904_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p0" title="Payments for royalties"&gt;80,000&lt;/span&gt;&#160;on the second anniversary
of the first commercial sale and $&lt;span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p0" title="Payments for royalties"&gt;100,000&lt;/span&gt;&#160;on the third anniversary of the first commercial sale and every year thereafter, for the
life of the AL001 License Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On
May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the
&#x201c;ALZN002 License&#x201d;), pursuant to which the Licensor granted the Company a royalty-bearing exclusive worldwide license limited
to the field of Alzheimer&#x2019;s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled &#x201c;Amyloid Beta
Peptides and Methods of Use,&#x201d; filed April 7, 2009 and granted May 29, 2012. On August 18, 2017, the Company entered into the First
Amendment to the ALZN002 License, on May 7, 2018, the Company entered into the Second Amendment to the ALZN002 License, on January 31,
2019, the Company entered into the Third Amendment to the ALZN002 License, on January 24, 2020, the Company entered into the Fourth Amendment
to the ALZN002 License, on March 30, 2021, the Company entered into the Fifth Amendment to the ALZN002 License, on April 17, 2023, the
Company entered into the Sixth Amendment to the ALZN002 License and on December 11, 2023, the Company entered into the Seventh Amendment
to the ALZN002 License (collectively, the &#x201c;ALZN002 License Agreement&#x201d;). The Seventh Amendment to the ALZN002 License modified
the timing of the payments of the license fees.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
ALZN002 License Agreement requires the Company to pay royalty payments of&#160;&lt;span id="xdx_90C_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pdd" title="Percentage of royalty payments on net sales of product"&gt;4%&lt;/span&gt;&#160;on net sales of products developed from the licensed
technology for ALZN002.&#160;&lt;span id="xdx_905_ecustom--DescriptionOfLicensesAgreements_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Description of licenses agreements"&gt;The Company has already paid an initial license fee of $&lt;span id="xdx_901_ecustom--InitialLicenseFees_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" title="Initial license fees"&gt;200,000&lt;/span&gt;&#160;for ALZN002. As an additional licensing
fee for the license of ALZN002, the Licensor received&#160;24,012 shares of Common Stock. Minimum royalties for ALZN002 are $&lt;span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p0" title="Payments for royalties"&gt;20,000&lt;/span&gt;&#160;on
the first anniversary of the first commercial sale, $&lt;span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p0" title="Payments for royalties"&gt;40,000&lt;/span&gt;&#160;on the second anniversary of the first commercial sale and $&lt;span id="xdx_900_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p0" title="Payments for royalties"&gt;50,000&lt;/span&gt;&#160;on
the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On
November 19, 2019, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications
of AL001 with the Licensor (the &#x201c;November AL001 License&#x201d;), pursuant to which the Licensor granted the Company a royalty bearing
exclusive worldwide licenses limited to the fields of (i) neurodegenerative diseases excluding Alzheimer&#x2019;s and (ii) psychiatric
diseases and disorders. On March 30, 2021, the Company entered into the First Amendments to the November AL001 License and on April 17,
2023, the Company entered into the Second Amendments to the November AL001 License (collectively, the &#x201c;November AL001 License Agreements&#x201d;).
The Second Amendments to the November AL001 License modified the timing of the payments for the license fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
November AL001 License Agreements require the Company to pay royalty payments of&#160;&lt;span id="xdx_90B_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pdd" title="Percentage of royalty payments on net sales of product"&gt;3%&lt;/span&gt;&#160;on net sales of products developed from
the licensed technology for AL001 in those fields.&#160;The Company paid an initial license fee of $&lt;span id="xdx_90E_ecustom--InitialLicenseFees_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Initial license fees"&gt;20,000&lt;/span&gt;&#160;for the additional indications.
Minimum royalties for November AL001 License Agreements are $&lt;span id="xdx_90A_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p0" title="Payments for royalties"&gt;40,000&lt;/span&gt;&#160;on the first anniversary of the first commercial sale, $&lt;span id="xdx_903_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p0" title="Payments for royalties"&gt;80,000&lt;/span&gt;&#160;on
the second anniversary of the first commercial sale and $&lt;span id="xdx_908_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p0" title="Payments for royalties"&gt;100,000&lt;/span&gt;&#160;on the third anniversary of the first commercial sale and every
year thereafter, for the life of the November AL001 License Agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;These
license agreements have an indefinite term that continue until the later of the date no licensed patent under the applicable agreement
remains a pending application or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory
body, or the date on which the Company&#x2019;s obligations to pay royalties expire under the applicable license agreement. Under the various
license agreements, if the Company fails to meet a milestone by its specified date, Licensor may terminate the license agreement. The
Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by
the Company while the Licensor remains the owner of any equity securities of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Additionally,
the Company is required to complete milestones and make payments on the due dates to the Licensor for the license of the AL001 technologies
and for the ALZN002 technology, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Original AL001 Licenses:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zCMacsEn2O14" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zpUCVNk3ZU8i" style="display: none"&gt;Schedule of contractual obligation, fiscal year maturity&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="width: 11%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____znVQ4K0acZc6" title="Due date"&gt;Completed September 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 38%"&gt;Pre-IND meeting&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;65,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zShljCml5rJ5" title="Due date"&gt;Completed June 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;IND application filing&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;190,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zme72DRKSHLe" title="Due date"&gt;Completed December 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Upon first dosing of patient in a clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;500,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z48eF4ZqBbv" title="Due date"&gt;Completed March 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Upon completion of first clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;1,250,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90E_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date"&gt;March 2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;10,000,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date"&gt;8 years from the effective date of the agreement&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Upon FDA new drug application approval&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td id="xdx_F08_zkszjVw2weqb" style="width: 9pt"&gt;*&lt;/td&gt;&lt;td id="xdx_F11_zh3FeDOQSOg5"&gt;Milestone met and payment made&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;ALZN002 License:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="width: 16%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: center"&gt;&#160;*&lt;/td&gt;
    &lt;td style="width: 82%"&gt;&lt;span id="xdx_90C_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_fKg_____zEp2k5XnqXz6" title="Due date"&gt;Completed January 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"&gt;Upon first dosing of patient in first Phase I clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;500,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_904_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"&gt;Upon completion of first Phase IIB clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;1,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"&gt;Upon first patient treated in a Phase III clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;10,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_904_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"&gt;Upon first commercial sale&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td id="xdx_F04_zqRn9VuSZ6id" style="width: 9pt"&gt;*&lt;/td&gt;&lt;td id="xdx_F15_zVcMtheF8a39"&gt;Milestone met and payment made&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Additional
AL001 Licenses:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" style="width: 11%; text-align: right" title="Payment"&gt;2,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date"&gt;March 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 38%"&gt;&#160;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;16,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_903_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date"&gt;August 1, 2029&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;First commercial sale&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.
      contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Pure">0.045</alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.>
    <alzm:DescriptionOfLicensesAgreements
      contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember"
      id="Fact000938">The Company has already paid an initial license fee of $200,000&#160;for AL001. As an additional
licensing fee for the license of the AL001 technologies, the Licensor received&#160;14,853 shares of Common Stock. Minimum royalties for
AL001 License Agreements are $40,000&#160;on the first anniversary of the first commercial sale, $80,000&#160;on the second anniversary
of the first commercial sale and $100,000&#160;on the third anniversary of the first commercial sale and every year thereafter, for the
life of the AL001 License Agreements.</alzm:DescriptionOfLicensesAgreements>
    <alzm:InitialLicenseFees
      contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember"
      decimals="0"
      id="Fact000940"
      unitRef="USD">200000</alzm:InitialLicenseFees>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_FirstAnniversaryMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">40000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_SecondAnniversaryMember"
      decimals="0"
      id="Fact000944"
      unitRef="USD">80000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_ThirdAnniversaryMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">100000</us-gaap:PaymentsForRoyalties>
    <alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.
      contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember"
      decimals="INF"
      id="Fact000949"
      unitRef="Pure">0.04</alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.>
    <alzm:DescriptionOfLicensesAgreements
      contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember"
      id="Fact000951">The Company has already paid an initial license fee of $200,000&#160;for ALZN002. As an additional licensing
fee for the license of ALZN002, the Licensor received&#160;24,012 shares of Common Stock. Minimum royalties for ALZN002 are $20,000&#160;on
the first anniversary of the first commercial sale, $40,000&#160;on the second anniversary of the first commercial sale and $50,000&#160;on
the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement.</alzm:DescriptionOfLicensesAgreements>
    <alzm:InitialLicenseFees
      contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember"
      decimals="0"
      id="Fact000953"
      unitRef="USD">200000</alzm:InitialLicenseFees>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_FirstAnniversaryMember"
      decimals="0"
      id="Fact000955"
      unitRef="USD">20000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_SecondAnniversaryMember"
      decimals="0"
      id="Fact000957"
      unitRef="USD">40000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_ThirdAnniversaryMember"
      decimals="0"
      id="Fact000959"
      unitRef="USD">50000</us-gaap:PaymentsForRoyalties>
    <alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.
      contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember"
      decimals="INF"
      id="Fact000961"
      unitRef="Pure">0.03</alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.>
    <alzm:InitialLicenseFees
      contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">20000</alzm:InitialLicenseFees>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_FirstAnniversaryMember"
      decimals="0"
      id="Fact000965"
      unitRef="USD">40000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_SecondAnniversaryMember"
      decimals="0"
      id="Fact000967"
      unitRef="USD">80000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_ThirdAnniversaryMember"
      decimals="0"
      id="Fact000969"
      unitRef="USD">100000</us-gaap:PaymentsForRoyalties>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact000971">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zCMacsEn2O14" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zpUCVNk3ZU8i" style="display: none"&gt;Schedule of contractual obligation, fiscal year maturity&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="width: 11%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____znVQ4K0acZc6" title="Due date"&gt;Completed September 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 38%"&gt;Pre-IND meeting&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;65,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zShljCml5rJ5" title="Due date"&gt;Completed June 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;IND application filing&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;190,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zme72DRKSHLe" title="Due date"&gt;Completed December 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Upon first dosing of patient in a clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;500,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z48eF4ZqBbv" title="Due date"&gt;Completed March 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Upon completion of first clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;1,250,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90E_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date"&gt;March 2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;10,000,000&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date"&gt;8 years from the effective date of the agreement&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Upon FDA new drug application approval&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td id="xdx_F08_zkszjVw2weqb" style="width: 9pt"&gt;*&lt;/td&gt;&lt;td id="xdx_F11_zh3FeDOQSOg5"&gt;Milestone met and payment made&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;ALZN002 License:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="width: 16%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: center"&gt;&#160;*&lt;/td&gt;
    &lt;td style="width: 82%"&gt;&lt;span id="xdx_90C_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_fKg_____zEp2k5XnqXz6" title="Due date"&gt;Completed January 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"&gt;Upon first dosing of patient in first Phase I clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;500,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_904_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"&gt;Upon completion of first Phase IIB clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;1,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"&gt;Upon first patient treated in a Phase III clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;10,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_904_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"&gt;Upon first commercial sale&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td id="xdx_F04_zqRn9VuSZ6id" style="width: 9pt"&gt;*&lt;/td&gt;&lt;td id="xdx_F15_zVcMtheF8a39"&gt;Milestone met and payment made&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Additional
AL001 Licenses:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" style="width: 11%; text-align: right" title="Payment"&gt;2,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date"&gt;March 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 38%"&gt;&#160;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" style="text-align: right" title="Payment"&gt;16,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_903_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date"&gt;August 1, 2029&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;First commercial sale&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember"
      decimals="0"
      id="Fact000973"
      unitRef="USD">50000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember"
      id="Fact000975">Completed September 2019</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_IndApplicationFilingMember_custom_AL001LicenseMember"
      decimals="0"
      id="Fact000977"
      unitRef="USD">65000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_IndApplicationFilingMember_custom_AL001LicenseMember"
      id="Fact000979">Completed June 2021</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponFirstDosingOfPatientInClinicalTrialMember_custom_AL001LicenseMember"
      decimals="0"
      id="Fact000981"
      unitRef="USD">190000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponFirstDosingOfPatientInClinicalTrialMember_custom_AL001LicenseMember"
      id="Fact000983">Completed December 2021</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponCompletionOfFirstClinicalTrialMember_custom_AL001LicenseMember"
      decimals="0"
      id="Fact000985"
      unitRef="USD">500000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponCompletionOfFirstClinicalTrialMember_custom_AL001LicenseMember"
      id="Fact000987">Completed March 2022</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AL001LicenseMember"
      decimals="0"
      id="Fact000989"
      unitRef="USD">1250000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AL001LicenseMember"
      id="Fact000991">March 2025</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponFdaApprovalMember_custom_AL001LicenseMember"
      decimals="0"
      id="Fact000993"
      unitRef="USD">10000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponFdaApprovalMember_custom_AL001LicenseMember"
      id="Fact000995">8 years from the effective date of the agreement</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponINDApplicationFilingMember_custom_ALZN002LicenseMember"
      decimals="0"
      id="Fact000999"
      unitRef="USD">50000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponINDApplicationFilingMember_custom_ALZN002LicenseMember"
      id="Fact001001">Completed January 2022</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember_custom_ALZN002LicenseMember"
      decimals="0"
      id="Fact001003"
      unitRef="USD">50000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember_custom_ALZN002LicenseMember"
      id="Fact001005">Upon first dosing of patient in first Phase I clinical trial</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponCompletionOfFirstPhaseIIClinicalTrialMember_custom_ALZN002LicenseMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">500000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponCompletionOfFirstPhaseIIClinicalTrialMember_custom_ALZN002LicenseMember"
      id="Fact001009">Upon completion of first Phase IIB clinical trial</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember_custom_ALZN002LicenseMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">1000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember_custom_ALZN002LicenseMember"
      id="Fact001013">Upon first patient treated in a Phase III clinical trial</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponFDABLAApprovalMember_custom_ALZN002LicenseMember"
      decimals="0"
      id="Fact001015"
      unitRef="USD">10000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponFDABLAApprovalMember_custom_ALZN002LicenseMember"
      id="Fact001017">Upon first commercial sale</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AdditionalAL001LicenseMember"
      decimals="0"
      id="Fact001020"
      unitRef="USD">2000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AdditionalAL001LicenseMember"
      id="Fact001022">March 2026</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-10-31_custom_FirstCommercialSaleMember_custom_AdditionalAL001LicenseMember"
      decimals="0"
      id="Fact001024"
      unitRef="USD">16000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-05-012024-10-31_custom_FirstCommercialSaleMember_custom_AdditionalAL001LicenseMember"
      id="Fact001026">August 1, 2029</us-gaap:OtherCommitmentsDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact001028">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z7gA3dXwZ5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_827_zoPfkIUYLZo4"&gt;EQUITY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
Company is authorized to issue &lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20241031_pdd" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of Preferred Stock, $&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20241031_pdd" title="Preferred stock, par value (in dollars per share)"&gt;0.0001&lt;/span&gt; par value. The Board has designated &lt;span id="xdx_901_ecustom--PreferredStockSharesDesignated_iI_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMu0nIwOihI1" title="Preferred stock shares designated"&gt;3,000&lt;/span&gt; shares as Series
A Convertible Preferred Stock and &lt;span id="xdx_90C_ecustom--PreferredStockSharesDesignated_iI_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z62UunYPZ2Ch" title="Preferred stock shares designated"&gt;6,000&lt;/span&gt; shares as Series B Convertible Preferred Stock. The rights, preferences, privileges and restrictions
on the remaining authorized &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares authorized"&gt;9,991,000&lt;/span&gt; shares of Preferred Stock have not been determined. The Board is authorized to create a new series
of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or
imposed upon any series of preferred shares.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Series A Convertible
Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
May 8, 2024, the Company and Orchid &lt;/span&gt;entered into a securities purchase agreement (the &#x201c;Orchid SPA&#x201d;) for the purchase
of up to &lt;span id="xdx_904_ecustom--NumberOfSharesPurchase_c20240501__20240508__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase"&gt;2,500&lt;/span&gt; shares of Series A Convertible Preferred Stock and warrants to purchase shares up to 2,000,000 shares of Common Stock in
several tranche closings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 10, 2024, the Company
sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase &lt;span id="xdx_90B_ecustom--NumberOfSharesPurchase_c20240501__20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase"&gt;80,000&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Exercise price"&gt;12.50&lt;/span&gt;, for a total purchase price of $&lt;span id="xdx_90B_ecustom--SharesPurchasePrice_pn3n3_dm_c20240501__20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zgzGrOum0xV2" title="Shares purchase price"&gt;1.0&lt;/span&gt; million. &lt;span style="background-color: white"&gt;The purchase price was paid by the surrender
and cancellation of a term note issued by the Company to Orchid of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentIssuedPrincipal_pp0p0_c20240501__20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zXzwQF5tCoC9" title="Principal issued"&gt;311,356&lt;/span&gt;, consisting of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zMBCeTuulB4b" title="Principal amount"&gt;310,000&lt;/span&gt; of principal and $&lt;span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zpFn6H5LQAz2" title="Accrued interest"&gt;1,356&lt;/span&gt; of accrued
and unpaid interest, $&lt;span id="xdx_901_eus-gaap--PreferredStockDiscountOnShares_iI_pp0p0_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_z8BGQ9STKAAh" title="Discount"&gt;100,000&lt;/span&gt; discount and net cash of $&lt;span id="xdx_903_ecustom--NetCash_iI_pp0p0_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zpxlSrse8SD3" title="Net cash"&gt;588,644&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 25, 2024, the Company
sold 150 shares of Series A Convertible Preferred Stock and warrants to purchase &lt;span id="xdx_903_ecustom--NumberOfSharesPurchase_c20240601__20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase"&gt;120,000&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Exercise price"&gt;12.50&lt;/span&gt;, for a total purchase price of $&lt;span id="xdx_907_ecustom--SharesPurchasePrice_pn3n3_dm_c20240601__20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zIKQwZpJ5xqa" title="Shares purchase price"&gt;1.5&lt;/span&gt; million. &lt;span style="background-color: white"&gt;The purchase price was paid in cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 19, 2024, the Company
sold 200 shares of Series A Convertible Preferred Stock and warrants to purchase &lt;span id="xdx_90A_ecustom--NumberOfSharesPurchase_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Number of shares purchase"&gt;160,000&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zafbXf1dFdg7" title="Exercise price"&gt;12.50&lt;/span&gt; to Orchid, for a total purchase price of $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zoVbk177Zodd" title="Value of common stock sold"&gt;2.0&lt;/span&gt; million. &lt;span style="background-color: white"&gt;The purchase price was paid in
cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 21, 2024, the Company
sold 250 shares of Series A Convertible Preferred Stock and warrants to purchase &lt;span id="xdx_901_ecustom--NumberOfSharesPurchase_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Number of shares purchase"&gt;200,000&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zKAk1brOgOW8" title="Exercise price"&gt;12.50&lt;/span&gt; to Orchid, for a total purchase price of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zToR3gYZfe7i" title="Value of common stock sold"&gt;2.5&lt;/span&gt; million less $100,000 discount. &lt;span style="background-color: white"&gt;The purchase
price was paid in cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On September 11, 2024, the
Company sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase &lt;span id="xdx_900_ecustom--NumberOfSharesPurchase_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Number of shares purchase"&gt;80,000&lt;/span&gt; shares of Common Stock with an exercise
price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_z2coswCRFvrk" title="Exercise price"&gt;12.50&lt;/span&gt; to Orchid, for a total purchase price of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zLHblYMy2TM6" title="Value of common stock sold"&gt;1.0&lt;/span&gt; million. &lt;span style="background-color: white"&gt;The purchase price was paid
in cash.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
&lt;/span&gt;Series A Convertible Preferred Stock &lt;span style="background-color: white"&gt;has a stated value of $1,000 per share and holders of
the Series A Convertible Preferred Stock are entitled to cumulative cash dividends at an annual rate of 15%, or $1,500.00 per share (&#x201c;Dividend
Amount&#x201d;), based on the stated value per share. Notwithstanding the foregoing, for as long as any share(s) of Series A Preferred
Stock shall remain outstanding, the Dividend Amount shall be paid either in shares of Series A Preferred Stock or cash, at Orchid&#x2019;s
discretion, in each case equal to the Dividend Amount. &lt;/span&gt;Each share of Series A Convertible Preferred Stock is convertible into shares
of Common Stock cased on the conversion price (&#x201c;Series A Conversion Price&#x201d;), which is defined as (a) the state value of the
Series A Preferred Stock being converted pus all accrued but unpaid dividends, divided by (b) the greater of (i) $2.50 per share (&#x201c;Floor
Price&#x201d;), and (ii) the lesser of (A) $15.00 and (B) 80% of the lowest closing price of the Common Stock during the three trading
days immediately prior to the date of the conversion. The Conversion Price is subject to adjustment in the event of an issuance of Common
Stock at a price per share lower than the Conversion Price then in effect, but not below the Floor Price. The Floor Price shall, however,
be adjusted for stock splits, stock dividends, combinations or similar transactions. The holders of the Series A Convertible Preferred
Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the
Delaware General Corporation Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion
price, for purposes of determining the number of votes the holder of Series A Convertible Preferred Stock is entitled to cast, shall not
be lower than $5.63 (the &#x201c;Voting Floor Price&#x201d;), which represents the closing sale price of the Common Stock on the trading
day immediately prior to the execution date of the Orchid SPA. The Voting Floor Price shall be adjusted for stock dividends, stock splits,
stock combinations and other similar transactions. Upon a liquidation event, the holders of Series A Convertible Preferred Stock receive
a liquidation preference ahead of holders of Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Series B Convertible
Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On January 31, 2024, the Company
and Ault Lending, LLC (&#x201c;Ault Lending&#x201d;) entered into a securities purchase agreement (the &#x201c;AL SPA&#x201d;) for the purchase
of up to 6,000 shares of Series B Convertible Preferred Stock and warrants to purchase shares up to &lt;span id="xdx_902_ecustom--NumberOfSharesPurchase_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_zhDraN3PYyU" title="Number of shares purchase"&gt;600,000&lt;/span&gt; shares of the Company&#x2019;s
Common Stock. The AL SPA provides that Ault Lending may purchase up to $6 million of Series B Convertible Preferred Stock in one or more
closings. &lt;span id="xdx_902_eus-gaap--TerminationLoansDescription_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember" title="Termination loans description"&gt;Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024,
and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025
(the &#x201c;Termination Date&#x201d;). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination
Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On January 31, 2024, the Company
sold &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Number of common stock sold"&gt;1,220&lt;/span&gt; shares of Series B Convertible Preferred Stock and warrants to purchase &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of common stock sold"&gt;122,000&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Exercise price"&gt;12.00&lt;/span&gt;, for a total purchase price of $&lt;span id="xdx_908_ecustom--SharesPurchasePrice_pn3n3_dm_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0KEHidyU69g" title="Shares purchase price"&gt;1.22&lt;/span&gt; million. &lt;span style="background-color: white"&gt;The purchase price was paid by the cancellation
of $&lt;span id="xdx_906_ecustom--CancellationsOfCashAdvances_pn3n3_dm_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmnxxTkCvA54" title="Cancellations of cash advances"&gt;1.15&lt;/span&gt; million of cash advances made by Ault Lending to the Company between November 9, 2023 and January 31, 2024 and a subscription
receivable of $&lt;span id="xdx_902_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iI_pp0p0_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9mj0Kr0NPki" title="Subscription receivable"&gt;70,000&lt;/span&gt;. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 26, 2024, the Company
sold &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240326__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Number of common stock sold"&gt;780&lt;/span&gt; shares of Series B Convertible Preferred Stock and warrants to purchase &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240326__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of common stock sold"&gt;78,000&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240326__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6yaqAszGUV3" title="Exercise price"&gt;12.00&lt;/span&gt;, for a total purchase price of $&lt;span id="xdx_907_ecustom--SharesPurchasePrice_pp0p0_c20240301__20240326__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkbZeq2agLX1" title="Shares purchase price"&gt;780,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 29, 2024, the Company
sold &lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240401__20240429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfveuRCKRuw6" title="Number of common stock sold"&gt;100&lt;/span&gt; shares of Series B Convertible Preferred Stock and warrants to purchase &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240401__20240429__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of common stock sold"&gt;10,000&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Exercise price"&gt;12.00&lt;/span&gt;, for a total purchase price of $&lt;span id="xdx_909_ecustom--SharesPurchasePrice_pp0p0_c20240401__20240429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkarlxSujqO" title="Shares purchase price"&gt;100,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
&lt;/span&gt;Series B Convertible Preferred Stock &lt;span style="background-color: white"&gt;has a stated value of $1,000 per share (&#x201c;Stated
Value&#x201d;) and does not accrue dividends. &lt;/span&gt;Each share of Series B Convertible Preferred Stock is convertible into a number of
shares of Common Stock &lt;span style="background-color: white"&gt;determined by dividing the Stated Value by $10.00&lt;/span&gt; (the &#x201c;Conversion
Price&#x201d;). The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than
the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders
of the Series B Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject
to applicable law provisions of the Delaware General Company Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq
regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock
is entitled to cast, shall not be lower than $8.73 (the &#x201c;Voting Floor Price&#x201d;), which represents the closing sale price of
the Common Stock on the trading day immediately prior to the Execution Date. The Voting Floor Price shall be adjusted for stock dividends,
stock splits, stock combinations and other similar transactions. Upon a liquidation event the holders of Series B Convertible Preferred
Stock receive a liquidation preference ahead of holders of Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The warrants have an exercise
price of $12.00 (the &#x201c;Exercise Price&#x201d;) and become exercisable on the first business day after the six-month anniversary of
issuance (the &#x201c;Initial Exercise Date&#x201d;) and have a five-year term, expiring on the fifth anniversary of the Initial Exercise
Date. The Exercise Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Exercise
Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="text-decoration: underline"&gt;At-the-Market Offering&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 3, 2024, the Company
entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the &#x201c;ATM Offering&#x201d;), as sales
agent to sell shares of its Common Stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through
the ATM Offering. On October 3, 2024, the Company filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately
$6.5 million in shares of Common Stock in the ATM Offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The offer and sale of the
shares will be made pursuant to the Company&#x2019;s effective &#x201c;shelf&#x201d; registration statement on Form&#160;S-3 and an accompanying
base prospectus contained therein (Registration Statement No.&#160;333-273610) filed with the SEC on August 2, 2023 and declared effective
by the SEC on August 10, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the six months ended
October 31, 2024, the Company sold an aggregate of &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240501__20241031_pdd" title="Number of common stock sold"&gt;755,888&lt;/span&gt; shares of Common Stock pursuant to the ATM Offering for gross and net proceeds
of $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240501__20241031_zuMqI5tVlFZf" title="Value of common stock sold"&gt;1.2&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="text-decoration: underline"&gt;Orchid SPA&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three months ended
October 31, 2024, Orchid converted &lt;span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20240801__20241031_pdd" title="Converted shares"&gt;649.5363&lt;/span&gt; shares of Series A Convertible Preferred Stock into &lt;span id="xdx_900_eus-gaap--ConversionOfStockSharesIssued1_c20240801__20241031_pdd" title="Number of shares issued"&gt;3,613,951&lt;/span&gt; shares of Common Stock. During
the six months ended October 31, 2024, Orchid converted &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20240501__20241031_pdd" title="Converted shares"&gt;712.0133&lt;/span&gt; shares of Series A Convertible Preferred Stock into &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20240501__20241031_pdd" title="Number of shares issued"&gt;3,787,284&lt;/span&gt; shares
of Common Stock.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact001030"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-31"
      decimals="INF"
      id="Fact001032"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <alzm:PreferredStockSharesDesignated
      contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">3000</alzm:PreferredStockSharesDesignated>
    <alzm:PreferredStockSharesDesignated
      contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001036"
      unitRef="Shares">6000</alzm:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">9991000</us-gaap:PreferredStockSharesAuthorized>
    <alzm:NumberOfSharesPurchase
      contextRef="From2024-05-012024-05-08_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementsMember"
      decimals="INF"
      id="Fact001040"
      unitRef="Shares">2500</alzm:NumberOfSharesPurchase>
    <alzm:NumberOfSharesPurchase
      contextRef="From2024-05-012024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">80000</alzm:NumberOfSharesPurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember"
      decimals="INF"
      id="Fact001044"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alzm:SharesPurchasePrice
      contextRef="From2024-05-012024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember"
      decimals="-3"
      id="Fact001046"
      unitRef="USD">1000000.0</alzm:SharesPurchasePrice>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2024-05-012024-05-10_custom_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="Fact001048"
      unitRef="USD">311356</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="Fact001050"
      unitRef="USD">310000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">1356</us-gaap:InterestPayableCurrent>
    <us-gaap:PreferredStockDiscountOnShares
      contextRef="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="Fact001054"
      unitRef="USD">100000</us-gaap:PreferredStockDiscountOnShares>
    <alzm:NetCash
      contextRef="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="Fact001056"
      unitRef="USD">588644</alzm:NetCash>
    <alzm:NumberOfSharesPurchase
      contextRef="From2024-06-012024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember"
      decimals="INF"
      id="Fact001058"
      unitRef="Shares">120000</alzm:NumberOfSharesPurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember"
      decimals="INF"
      id="Fact001060"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alzm:SharesPurchasePrice
      contextRef="From2024-06-012024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember"
      decimals="-3"
      id="Fact001062"
      unitRef="USD">1500000</alzm:SharesPurchasePrice>
    <alzm:NumberOfSharesPurchase
      contextRef="From2024-08-012024-08-19_custom_Warrant2024Member"
      decimals="INF"
      id="Fact001064"
      unitRef="Shares">160000</alzm:NumberOfSharesPurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-19_custom_Warrant2024Member"
      decimals="INF"
      id="Fact001066"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-08-012024-08-19_custom_Warrant2024Member"
      decimals="-3"
      id="Fact001068"
      unitRef="USD">2000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <alzm:NumberOfSharesPurchase
      contextRef="From2024-08-012024-08-21_custom_Warrant2024Member"
      decimals="INF"
      id="Fact001070"
      unitRef="Shares">200000</alzm:NumberOfSharesPurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-21_custom_Warrant2024Member"
      decimals="INF"
      id="Fact001072"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-08-012024-08-21_custom_Warrant2024Member"
      decimals="-3"
      id="Fact001074"
      unitRef="USD">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <alzm:NumberOfSharesPurchase
      contextRef="From2024-09-012024-09-11_custom_Warrant2024Member"
      decimals="INF"
      id="Fact001076"
      unitRef="Shares">80000</alzm:NumberOfSharesPurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-11_custom_Warrant2024Member"
      decimals="INF"
      id="Fact001078"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-09-012024-09-11_custom_Warrant2024Member"
      decimals="-3"
      id="Fact001080"
      unitRef="USD">1000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <alzm:NumberOfSharesPurchase
      contextRef="From2024-01-012024-01-31_custom_SeriesBConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementsMember_custom_AultLendingMember"
      decimals="INF"
      id="Fact001083"
      unitRef="Shares">600000</alzm:NumberOfSharesPurchase>
    <us-gaap:TerminationLoansDescription
      contextRef="From2024-01-012024-01-31_custom_SeriesBConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementsMember_custom_AultLendingMember"
      id="Fact001085">Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024,
and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025
(the &#x201c;Termination Date&#x201d;). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination
Date.</us-gaap:TerminationLoansDescription>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">1220</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001089"
      unitRef="Shares">122000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001091"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alzm:SharesPurchasePrice
      contextRef="From2024-01-012024-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact001093"
      unitRef="USD">1220000</alzm:SharesPurchasePrice>
    <alzm:CancellationsOfCashAdvances
      contextRef="From2024-01-012024-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact001095"
      unitRef="USD">1150000</alzm:CancellationsOfCashAdvances>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2024-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001097"
      unitRef="USD">70000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-03-012024-03-26_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001099"
      unitRef="Shares">780</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-03-012024-03-26_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001101"
      unitRef="Shares">78000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-26_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001103"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alzm:SharesPurchasePrice
      contextRef="From2024-03-012024-03-26_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001105"
      unitRef="USD">780000</alzm:SharesPurchasePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-04-012024-04-29_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001107"
      unitRef="Shares">100</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-04-012024-04-29_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001109"
      unitRef="Shares">10000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-29_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001111"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alzm:SharesPurchasePrice
      contextRef="From2024-04-012024-04-29_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001113"
      unitRef="USD">100000</alzm:SharesPurchasePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact001116"
      unitRef="Shares">755888</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-05-01to2024-10-31"
      decimals="-3"
      id="Fact001118"
      unitRef="USD">1200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-08-012024-10-31"
      decimals="INF"
      id="Fact001120"
      unitRef="Shares">649.5363</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-08-012024-10-31"
      decimals="INF"
      id="Fact001122"
      unitRef="Shares">3613951</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact001124"
      unitRef="Shares">712.0133</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-05-01to2024-10-31"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">3787284</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact001128">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_znkqk32mIFU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_825_zORL98nRK4Rl"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the Orchid
SPA, the Company &lt;span style="background-color: white"&gt;agreed to pay Ault Lending an origination fee of five percent (5%) of the total
gross proceeds we receive from Orchid upon each purchase of Series A Convertible Preferred Stock. During the three and six months ended
October 31, 2024, origination fees due to Ault Lending were $&lt;span id="xdx_904_ecustom--OriginationFees_c20240801__20241031_pp0p0" title="Origination fees"&gt;275,000&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--OriginationFees_c20240501__20241031_pp0p0" title="Origination fees"&gt;400,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <alzm:OriginationFees
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact001130"
      unitRef="USD">275000</alzm:OriginationFees>
    <alzm:OriginationFees
      contextRef="From2024-05-01to2024-10-31"
      decimals="0"
      id="Fact001132"
      unitRef="USD">400000</alzm:OriginationFees>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-05-01to2024-10-31" id="Fact001134">&lt;p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zOIy9JIQjvhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_826_z6zCBIQAHMHk"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;From November 1, 2024 to December
10, 2024, the Company sold an aggregate of &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241101__20241210_pdd" title="Number of common stock sold"&gt;201,543&lt;/span&gt; shares of Common Stock pursuant to the ATM Offering for gross and net proceeds of $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20241101__20241210_pp0p0" title="Value of common stock sold"&gt;280,000&lt;/span&gt;.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management has evaluated events
through the date the financial statement were available to be issued and determined that there have been no other events that occurred
that would require adjustment to our disclosures in the condensed financial statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-11-012024-12-10"
      decimals="INF"
      id="Fact001136"
      unitRef="Shares">201543</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-11-012024-12-10"
      decimals="0"
      id="Fact001138"
      unitRef="USD">280000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-05-01to2024-10-31" id="Fact001139">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-05-01to2024-10-31" id="Fact001140">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-05-01to2024-10-31" id="Fact001141">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-05-01to2024-10-31" id="Fact001142">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000669"
          xlink:label="Fact000669"
          xlink:type="locator"/>
        <link:footnote id="Footnote000684" xlink:label="Footnote000684" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with
an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per
share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB
ASC 260-10-45-14.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000669"
          xlink:to="Footnote000684"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000671"
          xlink:label="Fact000671"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000671"
          xlink:to="Footnote000684"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000975"
          xlink:label="Fact000975"
          xlink:type="locator"/>
        <link:footnote id="Footnote000996" xlink:label="Footnote000996" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Milestone met and payment made</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000975"
          xlink:to="Footnote000996"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000979"
          xlink:label="Fact000979"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000979"
          xlink:to="Footnote000996"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000983"
          xlink:label="Fact000983"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000983"
          xlink:to="Footnote000996"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000987"
          xlink:label="Fact000987"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000987"
          xlink:to="Footnote000996"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001001"
          xlink:label="Fact001001"
          xlink:type="locator"/>
        <link:footnote id="Footnote001018" xlink:label="Footnote001018" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Milestone met and payment made</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001001"
          xlink:to="Footnote001018"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
